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Cervical cancer is the 3rd commonest cancer occurring among women worldwide, behind breast 
and colorectal cancer. (Parkin et al. 1999) Screening via the use of cervical smears to detect 
preclinical disease has been successful in many countries in reducing mortality and incidence due 
to this malignancy. The purpose of this dissertation is to evaluate aspects of the New Zealand 
cervical screening program by: 
• Comparing trends in cervical cancer mortality before and after the introduction of screening 
by direct standardization of age-specific mortality rates 
• Calculating the positive predictive value of cervical cytology 
A centrally organized national program was launched in 1990 but prior to this screening activity 
has resulted in reductions in mortality. Direct standardization of mortality rates enables 
comparison of mortality across different time periods. A 50% reduction in mortality has taken 
place for women in the 1994-1996 period compared to 1954-1958. 
The use of the smear is not without some degree of inaccuracy. Errors occur as a result of human 
error and the imperfection of this instrument to adequately obtain specimens. Analysis of smear 
results using the national screening register correlating a cytological diagnosis with histology, 
proves this to be the case. However the absence oflarge amounts of histology give a biased 
estimate: the predictive value positive for high-grade lesions was 61.8-78%; and for low-grade 
lesions this was 25.3-62.1 %. 
The pathway to improvement is unlikely to lie in newer technology. Greater care in obtaining 
. . 
samples and reading slides will produce gains in efficiency in a service that is already performing 
well. 
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INTRODUCTION 
Most cancers of the cervix begin as atypical cells of the squamous epithelium at the 
squamocolumnar junction. With time atypical cells may progress in their degree of atypia 
through a spectrum of dysplasia known as cervical intraepithelial neoplasia CIN. The end of the 
spectrum of these precancerous changes is that of malignancy characterized by hallmark changes 
which can be observed microscopically as well as macroscopically. Chapters 1 and 2 describe 
the anatomy and pathology of cervical cancer and its precursor lesion CIN. Chapter 1 also 
contains a review of the etiology and international trends in mortality. Aspects related to the 
established risk factor of human papilloma virus (HPV) will be described separately to a review 
of other risk factors implicated in the etiology of cervical cancer. An analysis of epidemiological 
evidence linking HSV 2, oral contraceptives and smoking will be undertaken as their role in the 
development of cervical cancer is less clear. 
The Total Bethesda System which became established after 1988 is used internationally to 
classify cervical cancer and its precursors. Diagnosis and treatment is simplified by the new 
classification system but is not foolproof. This system and some of its weaknesses will be 
referred to in chapter 2. 
Chapter 3 describes the prevalence of preclinical disease and the mortality and incidence of 
cervical cancer among New Zealand women locating this in the international arena. Work by 
Cox and Borman (Cox and Borman 1994) documents the gradual decline in mortality and 
incidence of cervical cancer in New Zealand since the 1950's up to the time of the establishment 
of the national screening program, showing variations in trends for cervical cancer according to 
the year of birth. Predictive analyses by Cox and Skegg (Cox and Skegg 1992) using computer 
modelling will be referred to here to describe the possible future scenarios had there been no 
improvements in services relating to screening. 
The intricacies of smear-taking contribute to the first half of the 4th chapter. Many investigators 
have shown the variability of cervical samples according to which smear instrumentation is used. 
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Errors occurring with smear-taking come from a number of sources, but predominantly two areas, 
which will be described alongside estimates of the false-negative rate that occurs for the process. 
Newer technologies and the potential they have to improve the smear taking process compose the 
second half of chapter 4. 
Chapter 5 on 'Screening' incorporates elements of the previous chapters which relate to the 
pathology and natural history of cervical cancer and its precursors as well as the biology ofHPV 
infection. Specifically this chapter evaluates the screening test in terms of sensitivity, specificity 
and positive predictive value and effectiveness. Effectiveness in reducing mortality will be 
assessed by an examination of the international community's experience implementing a 
program. Also a review of case-control studies showing a decreased risk of developing cancer 
associated with screening ( or an increased risk of cancer associated with not screening) will be 
used to substantiate the effectiveness of screening. Issues considered here also include the modus 
operandi of a screening program. This will be evaluated in the context of World Health 
organization recommendations for the overall organizational aspects of a program. Other aspects 
of operation such as determining the screening interval will be derived from computer generated 
modelling. The final issue considered in this chapter is the worth of HPV screening which will be 
considered in the context of its sensitivity, specificity and predictive value. 
Methodology, results and findings relating to the positive predictive value and age-standardized 
mortality rates is contained in chapter 6 and 7 respectively from a secondary analysis of data 
obtained from the National Cervical Screening Register and mortality data from the Statistics 
Department. Interpretation of the positive predictive value of screening in chapter 6 is limited by 
absent data. The predictive value of cytology varies according to age and the type of lesion. It 
also shows that false positives and false negatives do occur but protocols for the management of 
abnormalities minimizes the effect of these imperfections. The success of the system is reflected 
in the progressive reductions in mortality described in the analysis of data in chapter 7. Chapter 8 
contains an overall evaluation based on these results and the experience of the international 
community as well as possibilities for new directions in cervical cancer screening. 
---~· ~---------·-·--·----
3 
1 CANCER OF THE CERVIX 
Chapter one describes the pathology, etiology and epidemiology of cervical cancer. 
Numerous changes in pathological classifications have taken place over the last fifty years. 
The most recent revision of concepts that have gained acceptance will be referred to in section 
1.2 on the descriptive pathology. Some etiological risk factors are well established such as 
human papillomavirus (HPV). Risk factors for which evidence is conflicting will be 
discussed in section 1.3. International and national trends are described and hypotheses to 
explain these trends will be put forward in section 1.5. 
1.1 THE NORMAL STATES OF THE CERVIX 
Squamocolumnar 
junction 
Fig. 1.1 transformation zone of cervix 
Original 
columnar } • From 
. . fetal 
Original lite 
squamous 
Changes to the transformation zone occur in late fetal development, adolescence and 
pregnancy whereby columnar cells at the squamocolumnar junction undergo squamous 
metaplasia forming squamous cells contiguous with the vaginal epithelium. (Chantler & 
Elstein 1991, Singer & Monaghan 1994) In the fetus the squamocolumnar junction lies 
within the endocervical canal and moves caudally with rapid proliferation of columnar cells 




During pregnancy the endocervical canal everts exposing it to the different vaginal 
environment with its higher ph and metaplastic transformation occurs with the formation of 










Fig. 1.2 Eversion of endocervix during pregnancy with metaplasia of the transformation zone 
SCJ = squamocolumnar juction 
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With menopause the transformation zon~ tends to retract within the ectocervix when estrogen 
levels fall with resultant atrophy. Squ~ous epithelium becomes thinner and less stratified. 
Fig. 1.3 Transformation zone of cervix pre and post menopause 









1.2 PATHOLOGY OF CERVICAL CANCER 
Estimates vary in the proportion of tumours thought to arise from the squamous and glandular 
components of the epithelial cells. Estimates range between 75% - 90% of cancers 
attributable to the squamous variety and 6%-10% of cancers arising from the glandular 
component giving rise to adenocarcinomas. Other rare histologic types include 
adenosquamous (which have a worse prognosis that either of the 2 former types), 
undifferentiated carcinomas, clear cell adenocarcinomas peculiar to diethylstilbesterol 
exposed women. The peak age of onset is reported also with slight variation by differing 
texts but for the majority of squamous lesions is thought to be around 45 years, 10 years 
earlier than that of adenocarcinomas. 
A clinical staging system developed by the International Federation of Gynaecologists and 
Obstetricians (FIGO) confers a prognosis according to the spread of disease. Table 1.1 
represents the latest revision to the staging system which has been in use for over 30 years. In 
addition to providing some index of survival rates it is also used to guide treatment decisions 
currently consisting of a combination of surgical excision and/or radiation. However this is 
no indicator to how disease will behave or respond to treatment. 
------~---·-- ------
Table 1.1 Five year survival rates for each stage given in percentages according to FIGO 1994 
classification: 
Stage O carcinoma in situ 
Stage 1 carcinoma confined to the cervix 
Stage lAl minimal microscopic invasion of the stroma 
No greater than 3 .Omm in depth 
Stage 1A2 microscopic invasion of the stroma greater than 3.0mm 
And less than 5mm in depth 
Stage lB invasive carcinoma of the cervix greater than 1A2 
Stage lBl lesions no greater than 4.0cm in size confined to the cervix 
Stage 1B2 lesions greater than 4.0cm in size confined to the cervix 
100% 
80-90% 
Stage 2 carcinoma extends beyond the cervix but not onto the 75% 
Pelvic wall; involvement of the vagina is limited to the 
Upper 2/3 
Stage 3 carcinoma has extended onto the pelvic walls and/or 35% 
Involvement of the lower 2/3 of the vagina 
Stage 4 invasive cancer that involves urinary, bladder and/or 







One of the main issues of contention has been what constitutes microinvasive disease. 
Microinvasive carcinoma is a subset of squamous lesions that can be treated conservatively 
with cone biopsy or simple hysterectomy as opposed to a radical hysterectomy and pelvic or 
lymph node dissection+/- radiotherapy.(Coppelson 1981, Crum 1997) Diagnosis is made by 
cone biopsy enabling the pathologist to judge tumor depth, (3mm deep minimal penetration 
being crucial to this diagnosis) confluency of growth pattern and capillary-lymphatic space 
invasion.(Coppelson 1981, Crum 1997) Non-neoplastic variants mimicking microinvasive 
changes include: (1 )inflammatory or reparative changes (including those of CIN); (2)blurring 
of the margins by artifact. (Crum 1997) 
Adenocarcinoma is situ - AIS, has been defined as a separate disease entity but may be 
contiguous with that of adenocarcinoma. (Crum 1997) The lesion is located at the 
squamocolumnar junction or sometimes slightly extending up the canal. A diagnosis of 
invasion is made if malignant glands extend into cervical stroma below the level of adjacent 
glands (Coppelson 1981, Crum 1997) or ifno adjacent benign glands are present, extension is 
2-3mm below the surface. (Crum 1997) Non-neoplastic mimics of AIS include glandular 
hyperlplasia, tubal metaplasia, inflammatory glandular reactions and radiated tissue. (Crum 
1997) 
Carcinomas have been classified by the degree of differentiation. Whilst this offers no 
prognosis it indicates the rate of growth; the well differentiated cancers exhibiting slower 
growth than the poorly differentiated types. (Jones 1979, Blaustein 1982, Tindall 1987) The 
striking features of the well-differentiated tumors is their retention of features resembling their 
original epithelial type (squamous or adeno) origin as opposed to poorly differentiated tumors. 
Attempts have also been made to classify tumors according to predominant cell type listed in 
table 1.2. There is considerable variation of opinion on the subtypes that fit within each 
category of adeno and squamous carcinomas. The extent of the difference in survival has not 
been established due to the lack of agreement and availability of data. 
l 
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Table 1.2 Histological classification of cancers based on the cell type according to WHO 
classification 
Squamous cell carcinoma Adenocarcinoma Other epithelial 
carcmomas 
Keratinizing Mucinous Adenosquamous 
Non keratinizing Endometriod Glassy cell 
Verrucous Clear-cell Adenoid cystic 
Papillary transitional Minimal deviation Adenoid basal 
Lympho-epithelioma like Serous Carcinoid 
Mesonephric Small-cell 
Undifferentiated 
Small cell and glass cell carcinomas having the poorest prognosis among all subtypes. (Benda 
1996) Overall adenocarcinomas carry a slightly worse prognosis than the squamous variety 
and this may be related to the more rapidly occurring lymph node metastases and local 




1.3 ETIOLOGICAL FACTORS IN THE PATHOGENESIS OF CERVICAL CANCER 
1.3.1 Male factors 
The observation of the low rates of cervical cancer in Jewish women led to the suspicion that 
poor penile hygiene related to uncircumcised men may be associated with the development of 
cervical cancer. This was spurred on by a finding of the tendency of mice to develop cervical 
cancer when subjected to stimulation by human smegma. (Heins et al 1958) However these 
findings linking cervical cancer to circumcision could not be simulated in other populations 
where circumcision was practiced. (Brinton et al., 1989, Kjaer et al 1991) 
British social class data from the early 60's associated husband's occupation to the risk of 
cervical cancer. Wives of fisherman , barge and boatmen, long distance lorry drivers, hotel 
and lodging house keepers carrying had the greatest prevalence of disease.(Beral 1974) 
The link between male factors and cervical cancer is now known to be due to the 
transmission of a venereal organism, with monogamous women whose partners had been 
polygamous (Zunzunegui et al. 1986,Brinton et al. 1989 ,) or reported a history of a variety of 
genital disease (Kjaer et al. 1991) having an increased risk of cervical cancer. 
1.3.2 The role of age at first coitus, parity and the number of partners. 
The observation of low rates of cervical cancer occurring in populations of nuns as opposed to 
the higher rates in married women and multiparous women pointed to the association of 
sexual activity with cancer. Factors that have clearly emerged as risks are those of early age 
at first coitus and multiple male partners. (Jones 1979, Blaustein 1982, Tindall 1987) 
Marriage and parity were confounders, with multiparous women being more like to have 
commenced a family at an early age. (Tindall 1987, Jones 1987) The strong association 
between sexual activity and cervical cancer became clearer with the momentum of new 
technology which was able to isolate the sexually transmissable agent - human papilloma 





1.3.3 Other infectious agents 
The search for a role for other infectious agents has been limited by the failure to take into 
account the HPV status of women. Another major difficulty in establishing a causal 
association particularly for sexually transmitted agents is differentiating their role as a marker 
of previous sexual activity from that of an etiological factor in causing disease. Infectious 
agents that have been implicated in the development of cervical cancer but for which no clear 
causal association has been established include Epstein-Barr virus, Treponema Pallidum, 
Neiserria Gonorrhea, cytomegalovirus. (Shiffman 1995) It is also unclear whether there is a 
causal role for immunosuppression in HIV infected women in the risk of progression from 
squamous intraepthelial lesions (SIL's) to cancer although such women have higher rates of 
SIL's. (Shiffman 1995) 
Research by Hildesheim (Hildesheim et al. 1991) taking into account the HPV status of 
subjects has demonstrated a causal association between Herpes-Simplex type 2 (HSV 2) and 
cervical cancer which suggests a synergistic effect with HPV. This study was a large case-
control study involving women from four regions in South America. Cases were newly 
diagnosed patients with invasive cancer in the region during an 18-month period excluding 
women who had previous treatment for cancer. Aged-matched controls came from the 
community and the local hospital. Hospital controls have the advantage of being similar to 
cases: the same selection factors that may have influenced case subjects to use a particular 
hospital or physician will be present for women in the hospital control group; there is the 
potential for a reduction in recall bias that may occur between community controls and cases 
as hospital subjects may be more aware of antecedent exposures. (Hennekens 1987) But the 
use of hospital control subjects compromises the external validity as hospitalized patients may 
differ from the general population with regards to exposure factors. (Hennekens 1987) The 
only factor that was commented on by researchers in this study was the similarity in 
seropositivity for HSV 2 between community controls and hospital control subjects. Diseases 
for which the control subjects were hospitalized may be associated with the risk factor under 
study (Hennekens 1987). For both categories of controls women were excluded if they had a 
previous hysterectomy or a history of cancer. 
The study had high participation rates and after a carefully standardized personal interview 
with all participants, an increased risk in the magnitude of 1.5 (95% CI 1.2-1.9, p-value not 







Odds ratios were adjusted for the number of sexual partners, age at first intercourse and HPY 
16/18 infection. The authors state that 'additional adjustment for education, ethnic origin, 
interval since last pap smear, oral contraceptive use and cigarette smoking, and HPY 6/11 did 
not affect the estimated OR. A further analysis by stratification was conducted to ascertain 
effect modification by age, oral contraceptive use, cigarette smoking and the number of 
pregnancies with little variation to the magnitude of the odds ratio however confidence 
intervals included the null value for a number of categories, p values have not been stated. 
When the joint effects of exposure to the two organisms were examined odds ratios suggested 
an interactive effect. In the presence of either one of the high-risk types of HPY (16 or 18) 
and a positive HSY 2 status, there was a 2-fold excess ofrisk for disease 2.6 (1.6-4.1 95%CI, 
p=0.03) compared to women who were positive for HSY 2 alone. ( odds ratios have been 
adjusted for the previously mentioned risk factors) When both HPY 16 and 18 were present 
amongst HSY 2 seropositive women the odds ratio increases to 8.8 (5.9-13.0 95%CI, p=0.03) 
These results are quite different to a population based case-control study on Spanish and 
Columbian women with invasive cancer or CIN 3, where testing took place for a range of 
sexually transmitted organisms. (de Sanjose et al. 1994) Age matched controls were derived 
randomly from the same population cases were acquired from. The willingness of women to 
give samples for HPY testing was lower- 63% compared to 90%+ in Hildesheim's study. 
When HPY status was accounted for there was no increased risk of cervical cancer associated 
with HSY 2. In a stratified analysis an increased risk associated with HSY 2 among HPY 
negative women failed to reach statistical significance due to the small number of cases and 
controls in each category. 
Results of this nature are dependent on the sensitivity of the tests to accurately detect the 
presence of infectious agents hence accurately classify women. The authors of the first study 
(Hildesheim t al. 1991) themselves report the low sensitivity of the Western Blot assay in 
classifying HSY 2 status and HPY status but state that the increased risk associated with HSY 
2 persists when misclassification is accounted for. The use of an in situ filter hybridization 
technique to detect HPY is less sensitive than the PCR method used in the second study by de 




1.3.4 Socioeconomic factors 
As mentioned previously, early British social class data demonstrated a socioeconomic 
differential with a tendency for cervical cancer to occur with greater prevalence amongst 
lower social classes. Such trends have been demonstrated on a global level by Faggiano et al. 
(Faggiano et al. 1997) This study using accumulated data across twenty-one countries, 
showed consistently higher mortality·and incidence rates in women for cancer of the cervix, 
uteri and oesophagus, for women in lower socioeconomic groups. 
Differences in the uptake of screening have been demonstrated among women according to 
their socioeconomic class. (Katz et al. 1994, Orbell et al. 1995) To answer the question as to 
whether this can be attributed to financial restrictions on accessing health care or differences 
in health beliefs between high and low socioeconomic groups, an analysis of trends among 
Canadian and American women representing two different philosophical systems of health 
care delivery by Katz et al. (Katz et al. 1994) shows the persistence of socioeconomic factors 
influencing screening. The study revealed that in Ontario where a universal insurance ensures 
\ 
no direct patient costs to screening and in the United States where private insurance markets 
characterizes health care that is procured by the wealthier members of society, women in both t-------societiesjn_the-higher-income-brackets-or-thosejn_possession_of_a_highede:v-eLo[education, 
f were more likely to opt for screening. (Katz et al. 1994) Thus factors beyond personal 
material resources such as health beliefs or the indirect costs of time spent at the doctor's 
surgery, may play a part in the socioeconomic differences associated with screening. 
Supporting evidence comes from a small English case-control study showing significant 
social class differences, with attitudes of embarrassment and anxiety predominating in the 
lower social classes, while perception of benefit was similar in unscreened and screened 
groups. (Orbell et al. 1995) These findings are comparable with a separate study of barriers 
to uptake of breast cancer screening where a lack of knowledge and negative attitudes as well 
as time and financial costs were significant barriers amongst low-income women. (Harper et 
al. 1993) Other factors relating to sexual behaviors which may vary according to social class 
include coitus at an early age, multiple sexual partners in both females and males with a 
greater prevalence of these factors among people in lower social classes. (Beral 1974, de 






1.3.5 Oral contraceptives 
There has been great difficulty in proving an association between oral contraceptive use and 
cervical cancer due to the interrelationship of sexual behaviors associated with oral 
contraceptive use and cervical cancer. Case-control studies linking oral contraceptive use to 
the development of cervical cancer (Who collaborative study 1985, Brinton et al. 1986, Bosch 
et al. 1992, Eluf-Neto et al. 1994, Zondervan et al. 1996, Yilato et al. 1999) that have shown 
an elevated risk may additionally be biased by the presence of HPV which was not 
consistently tested for in all studies. Microglandular hyperplasia is a benign lesion occurring 
in women using oral contraceptives. (Cotran et al. 1989) High levels of estrogen and 
progesterone receptors have been observed among women with cervical cancer. (Hahnel et al. 
1979, Ford et al. 1983) The exact biological mechanisms by which contraceptive pills cause 
cancer is still hypothetical. 
Case-control studies are good for assessing this type of disease and exposure pattern where the 
disease has a long latent period and would otherwise require lengthy follow-up periods if a 
prospective study design were used. The disadvantage lies in accurately assessing the time 
sequence of events between exposure and onset of disease. For example whether HPV 
exposure has occurred before the onset of disease or after. As described in chapter 1 and 2, 
the natural history of cervical cancer and its precursors is such that it can be assumed with that 
HPV infection has been the initiating event of a neoplastic progression however spontaneous 
resolution of the infection may also be the outcome of dysplastic changes. 
Study design varies among case-control studies consisting of a mixture of hospital case-
control studies, population based case-control studies and one study based at a family 
planning clinic. Control group participants derived from the population have the advantage of 
being generalizable to the general population from which case data was derived. This is 
particularly important in the study of oral contraceptive use as it has been shown that 
hospitalized patients are more likely to be oral contraceptive users. (West et al. 1984) 
Hospital based studies considered here showed similarity in patterns of oral contraceptive use 
between cases and controls. Generalizability is an issue for the study conducted at a family 
planning clinic by Zondervan et al. (Zondervan et al. 1994) which may not be representative 
of the general population. Hospital controls may also significantly differ to the general 
population since the disease for which women were hospitalized may be associated with risk 
factors under study. This was dealt with by the hospital based studies by the exclusion of 
-----~--------- ----------------~~----------------
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conditions associated with the disease or risk factor under study such as other gynecological 
malignancies, sexually transmitted diseases, thromboembolic conditions .... 
Respondent rates were high in all studies. Efforts to obtain accurate information involved 
basic measures such as applying a standard questionnaire by trained researchers and other 
novel ways such as the use of a lifetime calendar that linked contraceptive use with lifetime 
events. Some degree of recall bias is inevitable, producing bias in the classification of cases 
since they may have a better recall for pill exposure status. 
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Not all studies had matched controls. This is significant in the differences that may occur in 
the distribution of risk factors between cases and controls. However the major source of 
confounding - the influence of sexual behaviors was controlled for in the analysis by the use 
of multivariate logistic regression (with the exception of Zondervan et al. 's study) along with 
other variables such as smoking, parity, socioeconomic status, marital status and age at first 
intercourse. Interval since last screening smear is another confounder with the ability to 
decrease the risks associated with the development of cancer. The latter was not consistently 
accounted for across studies. Studies which sought to account for the presence of HPV 
(Bosch et al. 1992, Eluf-Neto et al. 1994, Yilato et al. 1999) performed stratified analyses 
according to HPV status. Oral contraception could not be established as an independent risk 
factor at a 0.05 level of significance in women that were either HPV negative or HPV 
positive. 
Overall the magnitude of adjusted odds ratios has been in the order of 1.2-4.4 with confidence 
intervals bordering or including the null value and p values for some studies indicating a 
chance association. A clear dose response relationship between the duration of oral 




Table 1.2 Studies associating oral contraceptive use with cervical cancer 
Study group Cases/ controls 
WHO 1985 726/5246 
Brinton et al. 1986 210/403 
Bosch et al. 1992 Spain 64/53 
Columbia 77 /53 
Eluf-Neto et al. 1994 
1-4 years of OC use 
>4 years of OC use 
Zondervan et al. 1996 
Yilato et al. 1999 
1.2.6 Smoking 
Exact numbers not stated 
77/48 
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Odds ratios, 95% confidence 
intervals, p values 
1.19 (1.1-2.1) p=.05 
1.5 (1.1 - 2.1) no p value 
given 
1.1 (.6-2.0) p=0.15 
1.3 (.9-2.0) p=.03 
1.16 (.44-3.06) 
2.51 (.87-7.3) 
x2 for trend 2.54 p=0.11 
4.44 (1.04 - 31.6) p=0.04 
3.64 (1.191 - 6.93) 
p<0.001 
Like many other types of cancer, smoking has been associated with cervical cancer. This is 
thought to be related to the metabolites in smoking suppressing local immune mechanisms. 
(Bornstein et al., 1995) Similar to the issues relating to oral contraceptive use to cervical 
cancer, it has been difficult to establish this as an independent risk factor because of the 
correlation of smoking with sexual behaviors hence HPV. Eluf-Neto et al.(Eluf-Neto et al. 
1994) was unable to demonstrate an increased risk associated with smoking in a multivariate 
analysis of results, when stratified by HPV status, HPV negative women were found to have 
an increased risk which was not significant at the 0.05 level. Bosch et al.'s work (Bosch et al. 
1992) yielded a weak association with an odds ratio of 1.5 (1.0-2.2 95%CI) p=0.05 in a 
multivariate analysis adjusted for HPV status. Zondervan demonstrated an increased risk for 
women smoking fifteen or more cigarettes daily- OR=3 .05 (1.27 - 7 .78 95%CI) p=0.02. A 
clear two-fold increased risk for developing cervical cancer associated with smoking emerged 
from Yilato's work - the odds ratio was 1.94 (1.32-2.85 95%CI) p<0.005 from a multivariate 
analysis that was not adjusted for HPV status. In a stratified analysis HPV positive women 
still experienced a doubling of risk - OR 2.34 (1.28-4.27 95%CI) p=O.O 1. 
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1.4 HUMAN P APILLOMA VIRUS (HPY) 
• j 
For the known 70 or so strains of HPV occurring in humans 24 subtypes are known to cause 
anogenital disease and 4 of these subtypes - 16, 18, 31 and 45 are associated with cervical 
cancer.(Schiffmann et al. 1995, Park et al.1995, Stoler 1996) Out of the 24 subtypes further 
subdivision is based on those with a low risk of lesion progression to cancer versus those with 
a moderate to high risk of lesion progression. This is based on the lack of finding of the low 
risk types in cancers. On the other hand the high risk ones are almost always present in 
cancers. 
1 .4 .1 Anatomy 
The virus consists of a 7900 base-pair double-stranded DNA genome and is divided into 
several regions that have different functions. E6 and E7 in the diagram below encode proteins 
that are responsible for causing cellular proliferation and transformation. They are also 
involved in the regulation of viral expression by replication and recruitment of the host 
anatomy for the latter purpose. The ORF region (not shown in the diagram) stands for open 
reading frames code for viral gene products. The URR region (upstream regulatory region) 
regulates ORF which is itselfregulated by E2 proteins. Integration of viral genetic material 
into host genetic material is associated with cancer. 
Figure 1.4 anatomy of the HPV genome 
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1.4.2 Typing 
Types 6 and 11 are associated primarily with genital warts which are non-malignant 
lesions.(Schiffmann et al. 1995, Stoler 1996) They have also been found in low grade lesions 
and only rarely in high grade lesions. Related virus's that produce a similar spectrum of 
disease in the cervix are types 42, 43, 44. (Park et al. 1995, Stoler 1996) 
Type 16 is found in all intraepthelial neoplasia as well as squamous 
malignancies.(Schiffrnann et al. 1995, Park et al. 1995, Stoler 1996) It is considered a 
moderate to high risk type and the other HPV virus's that produce similar changes are types 
31,33,35,52,58. (Park et al. 1995. Stoler 1996) 
HPV type18 is the other cancer causing prototype occurring predominantly in 
adenocarcinomatous lesions as well as penile and vaginal cancers.(Stoler 1996) (Refer to 
table 6 in appendix 4 for a summary of studies documenting the prevalence of HPV types 
according to the lesion) 
1 .4.3 Pathogenesis of cancer 
Viral integration disrupts the E2 gene expression which is a regulatory mechanism. Loss of 
this regulation is the basis for the subsequent changes that include activity of the E6 and E7 
regions that interact with endogenous cell regulatory proteins p53 and Rb enabling viral 
replication. The reserve cells at the transformation zone are the population from which 
squamous and glandular components are derived and have the capability to incorporate viral 
material. During replication of the reserve cells productive HPV expression is permitted but 
only when these cells are differentiating into their squamous or glandular components. 
The presence ofHPV may persist up to 10-20 years (Stoler 1996) with regression occurring 
in some cases. More often HPV infection tends to be transient - <12 months. (Hildesheim et 
al.1994, Evander et al. 1995, Romney et al. 1996,Ho et al. 1998) Age groups with the highest 
prevalence are those under the age of 30. (Schiffman et al. 1995, Mitchell et al. 1996) 
Cofactors such as sexual behaviors, cigarette smoking and host immunity factors are also 
thought to interact and influence viral behavior. The appearance of high risk types in low 
grade lesions as well as the presence of any HPV type in women with normal cytology, (Cox 
et al. 1995, Hall et al. 1996, Ferris et al. 1998) the imprecise knowledge of the progression of 
neoplasia in these women with normal cytology or low grade lesions and the absence of a 
vaccine limits the effectiveness ofHPV testing as a screening tool. 
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1.5 TRENDS IN INTERNATIONAL MORTALITY AND INCIDENCE 
Well before the introduction of organized screening programs mortality rates for cervical 
cancer were in decline in many countries.(Herrero 1996) This is thought to be due to the 
reduction in known risk factors, better access to treatment, and detection at earlier clinical 
stages. (Herrero 1996) However there is a huge socioeconomic division evident in the cancer 
statistics of developing countries where 78% of cervical cancers occur where this malignancy 
accounts for 15% of cervical cancers with a lifetime risk of 3%. (Parkin et al 1999) In 
developed countries it accounts for only 4.45% of new cancers in women carrying a lifetime 
risk of 1.1 %. (Parkin et al. 1999) The difference between low-incidence and high incidence 
countries may be as much as 10-fold with commensurate differences in mortality. 
j m < 9.7 GJ < 14.7 o < 2&.e G.'I < 38.0 • < n.4 I 
Fig 1.5 Estimated worldwide age-standardized incidence rates of invasive cervical cancer. Pisani P, Parkin DM, 
Munoz N, Ferlay J, Cancer and infection:estimates of the attributable fraction for 1990 
Whilst there are definitive ethnic group differences that are attributed to the prevalence of risk 
factors, ethnic variations within a population is also observable. For example, in the United 
States there is a higher incidence and mortality in cervical cancer amongst the American 
black population compared to the white population. (Herrero 1996) Since 1973 the rate of 
decline in incidence and mortality data for blacks has been greater compounded by a 
plateauing effect in the white population. (Herrero 1996) A similar situation occurring locally 
is the gap between New Zealand Maori and non-Maori. In 1989-91 the incidence rate of 
cervical cancer was 2.5 times higher that non-Maori. Research examining trends in Maori 
health for three time periods from 1974 showed increases of 14% in 1974-76 from 2.8 to 3.2 
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in 1981-83 and a further increase of 9% to 3.5 in 1989-1991 whilst non-Maori rates remained 
steady in these three time periods. (Pomare et al. 1995) Mortality rates have also been 3.8-4 
times higher amongst Maori compared to non-Maori between 1984-1991. (Pomare et al. 
1995) It is not known why these differences exist for Maori. 
Increases in incidence and mortality from cervical cancer for women under 39 began in the 
70's, in England, Wales, Scotland, Ireland, New Zealand and Australia. (Herrero 1996, Beral 
et al 1994) Increases in mortality at ages 35-39 occurred in the Nordic countries (excluding 
Finland) and Eastern European countries a decade later. (Beral et al 1994) This is thought to 
be due to the increased prevalence ofHPV infection and other risk factors. (Beral et al 1994, 
Boyle 1997) More recently Taiwanese figures have also demonstrated this upward trend in 
young women, which researchers thought were due to significant social changes in sexual 
behaviors, reproductive patterns and smoking habits. (Wang et al. 1996) 
A cohort effect with a bimodal distribution is present in New Zealand and U.K data. For the 
UK, women born around 1921 have high mortality rates during their middle aged years 
whilst those born between 1926-1931 have lower rates in their middle ages, and women born 
since 1935 have shown steadily increasing mortality and incidence rates. ( Parkin et al. 1985) 
This is similar to New Zealand where the highest mortality and incidence rates are 
experienced by cohorts born prior to 1921, and women born since 194 7 exhibit upward 
trends in cervical cancer incidence and mortality. (Cox et al. 1994) Graphical representations 
of New Zealand data are displayed in chapter 3. A cohort effect of increasing incidence and 
mortality for subsequent cohorts is apparent in Australia (Armstrong et al. 1981) and 
Taiwanese (Wang et al. 1996) data a decade later. The implication of the cohort effect 
exhibiting the upward trends with time is consistent with some mass population exposure to a 
risk factor. 
1.5.1 Correlation of trends with possible hypotheses and sources of bias: 
1.5.1.1 Data collection 
Improved reporting of data may have also resulted in spurious increases in mortality and 
incident statistics. However most of the upward trends took place in the 70's and early 80's -
a time when the U.K. and Australia in line with other developed countries had established 
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registries and protocols associated with cancer reporting. In the U.K. study a proportionately 
small number of deaths arose from the uterus 'site unspecified'. (Cook et al. 1984) The 
majority of such deaths occurred in women older than 55 which would be unlikely to 
influence the trends that affected women under 50. 
1.5.1.2 Classification bias 
The concept of microinvasive disease was not ratified until 1974 by FIGO. Previous to that, 
although there was recognition of microinvasive disease (since 1948 when the term was first 
coined) definition was debatable as to the depth of stromal invasion, vascular invasion, 
confluency of disease. Without a firm definition of the microinvasive and occult stages these 
stages may or may not have been reported as being cancerous lesions, thus under-reporting of 
numerator data may have taken place in a random manner resulting in apparent increases after 
its ratification. It is not known from those studies examining trends whether the latter was the 
case and exactly which criteria for inclusion of disease were used. However as delineated by 
FIGO staging, the inclusion or exclusion of microinvasive disease should have little impact 
on the mortality because of the high survival rate in this stage. 
1.5.1.3 Changing screening practices 
Increased detection by increased screening activity may play some role in inflating incidence 
data of disease. The logical conclusion would be a lower mortality due to improved survival -
theoretically through detection at an earlier stage. Only the Nordic countries ( excluding 
Norway) and some regions of Scotland had organized programs during the latter period of 
incremental trends. Changes in screening practice may also significantly alter incidence and 
mortality data such as a reduction in the recommended age at which screening should begin. 
'Gaps' in the screened age groups ie. recommendations concerning more screening for the 
more mature women or a low uptake of screening amongst young women or young women 
with symptoms being less likely to be screened because of the traditionally lower malignant 
potential in this age group, would explain the increments in trends for young women. 
1.5.1.4 False negatives 
The false negative rate for smears may be between 11 %-54%. (Shulman et al. 1974, Morel et 
al. 1982, Paterson et al 1984, Gay et al. 1985, Soost et al. 1991,Janerich et al. 1995) False 
negatives smears are smears containing malignant cells that escape detection within a given 
screening interval.(see section 4.1 for a detailed discussion on false negatives) A high false 
negative rate by missed detection of cancers will account for an increased incidence and 
mortality particularly if cancer in the young - the population that would most likely opt for 
smears, was not detected at very early stages of disease. A lack of population based studies 
on staging precludes any conclusions as to whether false negatives resulting in late stage 
disease may have impacted on mortality and incidence rates. 
1.5.1.5 Increasing incidence of adenocarcinoma in young women 
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For trends in cervical cancer among young women there was mounting evidence from 
population based surveys of an increasing incidence of adenocarcinoma in young women 
from the United States, Britain and Norway. In the United States where incidence and 
mortality were declining, Schwartz (Scwartz et al. 1986) found a two-fold increase between 
1973-1982 among women under 35 where squamous lesions were also shown to be have 
declined in the same age group. Chilvers et al. (Chilvers et al. 1987) using information from 
3 cancer registries in England found an increase in adenocarcinoma from 2.4 per million in 
1968-1972 to 6.6 per million in 1978-1982 for women under 35. Contrary to U.S figures was 
a two-fold increase in squamous lesions for the same age group over the same period of time. 
Norwegian surveys also showed a trend for increasing incidence of adenocarcinoma for 
women up to the age of 50 from 1971-1990, with a concomitant slight decline in the overall 
mortality from cervical cancer and incidence of squamous cancer. (Bjorge et al. 1993) 
1.5. 1.6 The role of chance and other factors 
As always, there is the possibility of random variation operating to produce temporary 
increases with no particular etiology contributing to trends. No studies have as yet accounted 
for varying hysterectomy rates or possible variations in treatment of precursor lesions or 
early stage microinvasive disease. 
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2 CERVICAL INTRAEPITHELIAL NEOPLASIA 
2.1 DISEASE DEFINITION AND OVERVIEW 
The precursor lesion of cervical cancer is CIN - cervical intraepithelial neoplasia, which itself 
consists of a spectrum of atypical changes of the cells graded in order of worsening changes 
in the epithelium of the cervix as shown in figure 2.1; CINI being the mildest changes to take 
place progressing to CIN3 which incorporates severely dysplastic changes and carcinoma-in-
situ. The Bethesda system which came into use after 1988 incorporates CIN classification 
and will be described in more detail in section 2.3 but some laboratories still continue to use 
the older CIN classification system. According to this internationally accepted system, CIN 1 
lesions have been classified with condylomas (lesions infected with HPV 6 or 11) as low 
grade squamous intraepithelial lesions(LSIL) and CIN 2 and 3 have been classified as high 
grade intraepithelial lesions (HSIL). This two tiered system is a predictor of disease severity 
and progress. It also provides a rationale for treatment based on the limited data on the 
known natural history of CIN. 
The initial changes that begin this continuum are usually due to the presence ofHPV 
infection. Initial infection is accompanied by productive viral infection with accompanying 
changes which may be self-limiting as described in section 1.4.3 giving rise to the diagnosis 
of LSIL. Therefore a smear with this diagnosis is repeated again in 6 months. Persisting 
abnormal change is referred for further evaluation by colposcopy. The steps in the 
management of abnormal smears will be described in section 2.4. Firstly a review of the 
cytopathology will follow in section 2.2 with a discussion of some of the limitations of the 
descriptive criteria that are used for classification purposes. 
PRECURSORS TO INVASIVE CARCINOMA OF CERVIX 
Cerviccd lntraepithelial Neoplasia 
GRADE 1 GRADE 2 GRADE J 
VERY MILD MILD MODERATE SEVERE IN SITU 
NORMAL DYSPLASIA DYSPLASIA DYSPLASIA DYSPLASIA CARCI-
NOMA 
MICRO INVASIVE CARCINOMA 
Fig. 2.1 Spectrum of change occurring in CIN 
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2.2 PATHOLOGY OF CIN 
2.2.1 Low and high grade lesions (LSIL/HSIL) 
Criteria by which the diagnosis of LSIL and HSIL is made includes the degree of cellular 
differentiation, nuclear abnormalities and mitotic activity. (Anderson 1990) Additionally the 
new Bethesda system of incorporating cellular changes associated with HPV - that of 
koilocytosis, with CIN 1 has introduced a new distinction between LSIL's and HSIL's. 
A low grade lesion is distiguished by thickening of the epithelium with koilocytotic atypia in 
the middle and upper portions of the epithelium.(Crum 1997) Koilocytotic atypia involve a 
number of abnormal changes at the cellular level including those of variation in nuclear size, 
hyperchromasia (the presence of fine granular chromatin in the nucleus or an appearance of 
increased nuclear densitiy) and binucleation or mutlinucleation and perinuclear 
halos.(Kurman et al. 1991, Crum 1997) These changes may occur with any type ofHPV 
infection. HSIL's share many of these characteristics but the nuclear atypia occurs in all 
layers at least in a portion of the lesion. The mitotic activity - an indicator of cell replication 
and division, is enhanced in HSIL' s. The qualitative differences on Pap smear between a 
LSIL and HSIL are distinct: the nuclei of an HSIL vary markedly in contour and they are not 
only hyperchromatic but contain irregular or coarsely distributed chromatin granules; the 
cells ofHSIL are usually smaller and less mature than those ofLSIL; nuclear size is the same 
but the nuclear-to-cytoplasmic ratio (N/C) is increased because the cells are smaller. (Crum 
1997) 
Despite strict criteria for judging between low and high grade lesions, it is possible that the 
two coexist (Crum 1997), giving rise to false negatives as discussed in chapter 4. A number 
of non-neoplastic changes and benign conditions mimic LSIL including those of: (!)reactive 
epithelial changes; (2) prominent cytolplasmic halos in the absence of nuclear atypia; (3) mild 
nuclear enlargement with hyperchromasia and small concentric halos seen in inflammatory 
conditions such as trichomoniasis (vaginal bacterial infection); (4) conditions of maturation 
disturbance produced by pregnancy, postpartum or menopausal states. ( Crum 1997) Yet 
another variant ofLSIL's in PIM - papillary immature metaplasia. (Crum 1997, Mosher et al. 
1998) It has been demonstrated to be associated with high grade lesions as well as low grade 
lesions. (Crum 1997, Mosher et al. 1998, Trivijitslip et al. 1998) 
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The Bethesda system of combining CIN2 and CIN3 into a single category should reduce some 
of the inter-observer variability that has occurred in the past in distinguishing them. (Ismail et 
al. 1990) Regardless of the difficulties associated with reproducibility , the management of 
the two lesions is the same. A differential diagnosis ofHSIL includes (!)reactive /reparative 
epithelial changes occurring sometimes in HPV infection;(2)immature squamous metaplasia 
growth patterns also occurring with HPV infection;(3)maturation disturbances of older 
women;(4)irradiated tissue;(5)infection with a number of agents ie.Chlamydia or HSV 
(Anderson 1990, Crum 1997) 
Despite the more simplified system of two grades the inter-observer differences in 
histopathological diagnosis by smear and biopsy is large. (Creagh et al. 1995, McCluggage et 
al. 1996, Lee et al. 1997) Ongoing debate about smear cytology has been flavored by the 
suggestions of a British Working Party advocating a new criteria - "basal abnormalities of 
uncertain significance" - BAUS. (Anderson et al. 1991) These changes are not typical of CIN 
1 but cannot be unequviocally allocated to a non-neoplastic process. (Anderson et al. 1991) 
2.2.2 Atypical squamous cells of uncertain significance (ASCUS) 
ASCUS represent a diagnosis of uncertainty, falling short of the diagnostic criteria of SIL's 
but not typical of inflammation or repair. In the past atypical changes were used to refer to 
inflammatory, benign reactive as well as preinvasive cellular changes, leaving the consulting 
physician with a mild quandary as to the appropriate follow-up. Under the Bethesda system 
reactive and inflammatory changes are classified separately. 
Cellular changes of ASCUS are similar to a koilocytic appearance with nuclear atypia and 
halos but to a lesser degree than SIL's. (Crum 1997) Sometimes immature squamous 
metaplasia may be present with an accompanying increased N/C ratio. When this is severe 
enough a diagnosis of a high grade lesion will be made. Smears from post-menopausal 
women contain atrophic cells warranting the diagnosis of atypia. A spectrum of inflammation 
may result in atypical repair processes. Such changes may be difficult to distinguish from 
SIL or invasive carcinoma. In an overview of studies correlating a smear diagnosis of 
ASCUS with biopsy proven SIL, Crum (Crum 1997) found that between 7%-55% ASCUS 
lesions diagnosed by cytology in fact were SIL's on histology. 
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2.2.3 Progression / Regression rates 
The natural history researchers have attempted to elucidate in tables 2.1 and 2.2 has been 
compiled by William Chanen and presented at a valedictory symposium at Melbourne. 
Cumulatively these suggest the proportion of CIN2 lesions which progress is greater than 
CINI. In a review of pathological studies by Ostor 1993, regression, persistence and 
progression of CIN3 to invasive cancer was estimated at 32%, 56% and> 12%. Not given in 
these tables are the transit times and length of observation. Years of follow-up to establish 
persistence of lesions have been in the range of 6-12 years. The general consensus is that high 
grade lesions tend to be more progressive in character than low grade lesions. 
Table 2.1 natural history of CIN 1 
Diagnosis by Regression range = Persistence range= Progression range = 
Cytology (8 studies) 6-62% (av.36%) 9-63% (36%) 13-60% (29) 
Biopsy (8 studies) 26-83% (49%) 8-65% (36%) 6-43% (15%) 
Chanen W. 1990 
Table 2.2 natural history of CIN 2 
Diagnosis by Regression range = Persistence range = Progression range = 
Cytology ( 4 studies) 31-50% (av.41 %) 9°-46% (28%) 14-60% (31 %) 
Biopsy (2 studies) 33-57% (45%) 16-49% (32%) 18-27% (23%) 
Chanen W. 1990 
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2.3 THE BETHESDA SYSTEM (TBS) 
This two tiered system categorizing lesions into high grade and low grade lesions (HSIL, 
LSIL) was first recommended by the National Cancer Institute in 1988 and is universally used. 
The term CIN still continues to be used. 
Each smear specimen is reported with respect to its adequacy, a general categorization as to 
whether or not the smear is within normal limits, and a descriptive diagnosis based on the 
following categories: 
(I )Benign Cellular changes- which may imply infection from any organism 
(2)Reactive epithelial changes - occurring in inflammation and the repair process, radiation 
or in response to intrauterine contraceptive devices 
(3)Epithelial cell abnormalities: 
Squamous cells 
• atypical squamous cells of undetermined significance (ASCUS) 
• low grade squamous intraepithelial lesion (LSIL) encompassing CINI and/or HPV 
• high grade squamous intraepithelial lesion (HSIL) encompassing CIN2, CIN3, carcinoma 
in situ (CIS) 
• squamous cell carcinoma 
Glandular cells 
• endometrial cells in a post-menopausal woman who is not on hormone replacement 
therapy 
• atypical glandular cells of undetermined significance (AGUS) 
• endocervical adenocarcinoma 
• endometrial adenocarcinoma 
• extrauterine adenocarcinoma 
• adenocarcinoma not otherwise specified 
2.4 MANAGEMENT OF THE ABNORMAL SMEAR 
Colposcopy - the practice of viewing the cervix by staining and magnification is the follow-
up investigation of persistently abnormal low grade lesions and all high grade lesions. 
Current protocols recommend that this should take place within 6 months of a low grade 
lesion and within 1 month of a high grade lesion occurring on smears. 
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Because of the inter-observer variation that occurs with colposcopy minimum standards for 
colposcopists have been recommended. Thus smears with asterisks on figure 2.2 should be 
examined by an experienced colposcopist- someone with a minimum of 5 years post 
fellowship experience and managing at least 150 new colposcopy cases each year ( and where 
appropriate supervise at least 75 teaching cases each year) and be an active member of a 
multidisciplinary team involved in the ongoing audit of the cytology, colposcopy and 
histology of women presenting with abnormal smears. 
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Fig. 2.2 Flow diagram for the management of an abnormal smear according to national guidelines. 
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• Ablative therapy in which the lesion is destroyed - may be electocoagulation, 
cryocautery, needle diathermy or laser. 
• Excision biopsy - large loop excision, laser conization, cone biopsy which is indicated 
when the whole lesion cannot be visualized or if there is a suspicion of invasive disease. 
It is also a definitive treatment for women with early microinvasive disease. 
• Hysterectomy - for women with both a cervical abnormality and other gynecological 
pathology. It is also used for women with persistent disease who have finished child-
bearing 
Follow up treatment is that of colposcopy and a smear in 4-6 months after treatment with 
further cytological follow up as shown in figure 2.2. 
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3 EPIDEMIOLOGY OF CERVICAL CANCER AND ITS 
PRECURSORS IN NEW ZEALAND 
3.1 PREVALENCE OF CIN 
Prevalence estimates are based on data available for the decade of the 80's shown in the 
studies in table 3 .1. Since the prevalence of CIN is related to the social behaviors of age at 
first intercourse, number of partners, smoking etc., changing patterns of these risk factors in 
the 90' s may invalidate the figures in table 3 .1. The Christchurch study contains incident data 
but will be included here for comparison. Incidence data is a measure of the number of new 
cases of disease and is influenced by the rate of occurrence of disease. (Hennekens 1987) 
Thus the higher values occurring in the Christchurch study relative to the prevalence 
estimates of the other studies may reflect a spurious increase in the number of women 
developing disease at the time the study was conducted. 
Studies come from a variety of settings. The smallest study in terms of numbers is the 
Auckland study .. External validity is not so severely compromised because the results of 
smears of almost all women for the whole region were used. The population of the region can 
be generalized to the rest of the country to some extent. However more diversity of ethnicity 
of the Auckland population limits comparison to the rest of New Zealand. External validity 
and generalizability was more an issue for the Christchurch study as it was confined to the 
population of women using family planning services. Therefore random variation or a high 
concentration of known risk factors for cervical cancer among the women attending the clinic 
may have given rise to the doubling of abnormalities in 1983 compared to 1982 and a tripling 
effect in 1985. The New Zealand Contraception and Health Study group is reflective of the 
ethnic and social distribution of the New Zealand population acquiring results from 9302 
women from eight regions in New Zealand however this is limited. However limits to 
generalizabilty occur as the study population was limited to women 20-39 years of age. 
Criteria for reporting abnormality varied. The Christchurch study included all abnormal 
smears which included any form of atypical change as well as carcinoma in situ. ( another 
reason for the high incidence in the study compared to prevalence estimates in other studies) 
The New Zealand Contraception and Health study restricted abnormals to CINl-3 in their 
final result as did the Auckland regional study and the Lower Hutt community laboratory 
data. 
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Age range for the prevalence of CIN was somewhat similar. In Lower Hutt the greatest 
prevalence for CIN was in the 15-34 age group. Christchurch reported an average age of28.9 
for its CIN3 patients but did not comment on the age distribution of the rest of the population 
with abnormalities. CIN lesions among Auckland women were found to reach a peak among 
40 year olds then subsequently decline. These figures will also be influenced by the age 
groups which have the greatest uptake in screening. Researchers comment that in the Hutt the 
greatest percentage of smears come from women under 3 5. 
Table 3.1 Prevalence of abnormalities on smears in varying studies 
Study Year Total number of %abnormal 
smears 
Christchurch 1982 6348 5.53 
family planning 
Hicks et al. 1987 1983 7076 10.38 
1984 7835 5.35 
1985 7599 17.1 
NZ Contraception 1980-86 9302 4.3 
and Health group 
1989 
Auckland Jones et 1985 4019 5.3 
al. 1988 
Lower Hutt 1987/1988 23,820 5.3 
McCafferty et al. 
1989 
3.2 INCIDENCE AND MORTALITY EXPERIENCE IN NEW ZEALAND 
Mortality rate (per 
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Fig.3.1 Mortality rates of cervical cancer 1954-1990 Fig.3.2 Incidence rates of cervical cancer 1952-90 
(from Cox and Borman Cervical cancer in New Zealand:national and regional trends. 
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Mortality rates from 1954 show declines for the 40+ age group, whereas the rates for women 
under 40 remain constant and increase slightly for the 20-29 age group. Incidence rates reflect 
mortality, however pronounced increases occur in women under 50 from 1967-71. This 
coincides with the launching of mass screening initiatives in some provinces in the 1960's. 
(Mcindoe 1964, Baeyertz 1965, Marshall 1966) 
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Fig.3 .3 Mortality rates by age and birth-cohort Fig. 3 .4 Incidence rates by age and birth-cohort 
From Cox and Borman Cervical cancer in New Zealand:national and regional trends 
Graphs in figure 3 .3 and 3 .4 illustrate the differing experience of cancer mortality and 
incidence dependent on the era of birth. All cohorts demonstrate a trend of increasing 
incidence and mortality with age. For women under 45 the birth cohorts of 1947 and those 
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occurnng subsequently, exhibit the highest incidence and mortality rates, suggesting either 
some mass population exposure to a risk factor or an absence of screening in young women. 
Reductions in mortality among women in older age groups for successive birth cohorts can be 
attributed to improvements in treatment techniques and/or the success of screening. The 
absence of a traditional 45-55 peak incidence in the 1927 and 1937 birth cohorts reflect the 
impact of screening activity that occurred in the 60' s when this age group had reached their 
30's and 40's. The latter effect should theoretically would also have a latent impact in the 






















3.3 PROJECTIONS OF CERVICAL CANCER MORTALITY IN NEW ZEALAND 
In 1992 Cox and Skegg used a computer generated statistical model to predict the future 
burden of disease based on modeling previous incident and mortality data. The modeling 
accounted for age, period and birth cohort effects.(figures 3.5 and 3.6) 
P 1 is the period effect assumed with no improvement in overall screening or survival. 
P2 represents immediate improvement in the overall organization of screening in New 
Zealand using a deflating value of 15% for each 5 year period. 
C 1 are estimates of risk based on the most recent three birth cohorts. 
C2 is the scenario of improved health education about risk factors - set at Yz of the estimate 












1954-58 1964-68 1974-78 1984-88 1994-98 2004-08 
Time period 
Fig. 3.5 Trend and projections of the cumulative mortality rate 0-74 years, for c~rvical cancer in New Zealand 

















1954-58 1964-68 1974-78 1984-88 1994-98 2004-08 
Fig.3.6 Trend projections of the incident rate for 0-74 years, for cervical cancer in New Zealand 
(Cox and Skegg Projection of cervical cancer mortality and incidence1992) 
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In the absence of educational measures and improved organization of screening services, the 
model predicts and increase in mortality from cervical cancer - Pl Cl figure 3.5 and a greater 
increase in incidence in cervical cancer - P 1 C 1 figure 3. 6. The greatest improvements in 
mortality and incidence of cervical cancer that can be expected is the scenario of improved 
screening and improved educative measures -P2C2 figure 3.5 and 3.6. In the absence of 
educative measures, improvement in screening services alone will still have a major impact on 
lowering mortality and incidence - P2Cl figure 3.5 and 3.6. The potential flaws in these 
predictions are the assumed values of the decreases that occur with education and improved 
screening used to generate the predictions. They are most likely to based on the experience of 
other countries hence there has to be a degree of uncertainty as to how generalizable they are 
to New Zealand. Secondly a 'closed- loop' scenario is assumed here where the changes to 
the population structure are minimal based on low fertility, medium short term migration and 
zero long term migration. This assumption is likely to hold true for the forseeable short term 
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3.4 COMPARISON OF MORTALITY ACROSS 36 SELECTED COUNTRIES 
Work presented in this section has been conducted by Beral (Beral et al.1994) in conjunction 
with the international agency for research on cancer (IARC) describing mortality trends for 36 
countries for several different time periods since 1950. Incidence data has not been analyzed, 
the authors stating that fluctuations in classification and a reduced availability of incidence 
data in some countries would compromise the validity results. 
For age-adjusted mortality rates, New Zealand ranks in the middle for the selected countries. 
Eastern European, South American and some Scandinavian countries display higher mortality 
statistics than New Zealand, whilst nations of similar mortality experience are those of the 
U.K., Germany and Switzerland. Nations with the lowest mortality statistics - North 
America, Netherlands and Finland, are the countries that have had a history of organized 
screening predating the programs in New Zealand and U.K by more than a decade. (refer to 
chapter 5) 
Fig.3.7 Age adjusted mortality rates for 36 selected countries (Beral et al. Cervical cancer 1994) 
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4 DIAGNOSTIC CYTOLOGY 
Diagnosis of cervical cancer in its early stages is by retrieval of cells from the region of the 
cervix. In 1941 Papanicolaou and Traut proposed the sampling of vaginal secretions to detect 
cancer. Ayre (1951) improved the sampling by introducing a wooden spatula moulded to fit 
the cervix for cell collection. A brief description of current methods for obtaining samples 
will be summarized followed by an analysis of sources of error in section 4.2. Recent 
developments in cytological analysis by new slide preparation techniques and image analysis 
devices will be overviewed in section 4.3 alongside their benefits and weaknesses. 
4.1 SAMPLING METHODS 
The 3 instruments in use today- cervibroom, brush and an Ayre's spatula, pickup cervical 
cells and surrounding secretions, which are then smeared onto a glass slide using an aerosol to 
fix the specimen. Staining methods in the laboratory then allow the slides to be read. 
Controversy exists as to the adequacy of these sampling instruments particularly in their 
differential abilities to obtain samples from the endocervical canal, (Boon et al.1986, Taylor 
et al.1987, Anderson et al.1988, Spurrett et al.1989 Van Erp et al.1989) with the cytobrush 
proving to be superior in sampling the endocervical canal. (Boon et al. 1986, Taylor et 
al.1987, Spurrett et al.1989, Van Erp et al.1989) However the combined technique of brush 
and spatula is better than 1 technique in isolation for sampling the transformation zone. (Boon 
et al.1986, Spurrett et al. 1989, Chang et al.1989) 
Sources of error occur due to specimens being obscured by inflammation or blood; errors of 
interpretation due to misdiagnosis by the pathologist; sampling errors either due to 
insufficient exfoliation of cells or lesions beyond the reach of sampling instrument or poor 
sampling technique on the part of the smear taker. Methods for reduction in error include 
double reading of specimens by multiple pathologists and repeat sampling when inadequate 
























4.2 FALSE NEGATIVES 
An estimation of false negatives can at best be only an estimation. Women with cancer or 
dysplastic lesions that have had previously normal smears within some given time interval are 
considered to be failures of screening. The previously 'normal' smear of these women either 
contain malignant cells which have escaped detection or the sample was not representative of 
the state of the cervix, giving rise to false negative smears. The numerator is the proportion 
of women that have disease for which a previous smear is negative (FN) and the denominator 
is the total number of women with disease. (True positives -TP + FN) (Walter 1998) False 
negatives for each disease criteria should be categorized separately. A study design to 
determine false negatives may utilize one of several methods: ( 1) Selecting cases of disease 
for which a previous smear has been abnormal within a given time-frame - interval cancer 
rate,(Forrest 1986) has been the preferred method for most studies in their calculation of false 
negatives. (2) Following a sample of known disease-free women for a period of time 
observing for the development disease, a methodology used by one group of researchers 
(Shulman et al. 1974) who then selected false negatives on the basis of a previous normal 
smear within a given time-frame. (3) Another method is the systematic re-examination by a 
repeat smear of a large group of screened women soon after an initial normal smear. (4) 
'Seeding' -placing known false negatives amongst a re-screened batch of negative slides. 
( although the latter method is more commonly use to test inter-rater reliability of cytologists) 
The screening interval is crucial to determining the false negatives. If the American Cancer 
Society's three year interval recommendation for low risk women to have screening is 
applied, then the false negative rate for diagnosing cancer from studies has been calculated to 
be in the order of 11.2%-20%. (Morel et al. 1982, Paterson et al 1984, Gay et al. 1985, Soost 
et al. 1991,Janerich et al. 1995) Shulman et al. (Shulman et al. 1974), whose observations 
included categories of dysplasia observed rates of up to 54%. 
The studies in which re-examination of slides of known cases with previously normal smears 
took place, false negatives were found to be semi-evenly distributed between sampling errors 
and differences in interpretation of smear findings. A smaller number of 'normal' slides on 
re-examination could be attributed to sub-optimal sampling specimens. Sensitivity may be 
increased by testing in parallel, (Hennekens 1987) thus reducing the false negative rate. For 
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the smear process this would mean obtaining dual specimens either at once or soon after the 
first sample. This method of duplicate sampling has been tested by several 
investigators.(Sedlis et al. 1974, Davis et al. 1981, Beilby et al. 1982) The aim of these 
studies was not to calculate a false negative rate, but to compare the degree of discrepancies 
occurring between two simultaneously taken samples. Differences in the results obtained 
from the two specimens were found to be due mainly to sampling error. Researchers noted a 
reduction in error rate with the dual sampling technique however the magnitude of error 
reduction varied. For example Davis et al. (Davis et al. 1981) states a 10% increase in yield 
of a range of abnormalities detected by a dual sampling method. Sedlis et al. (Sedlis et al. 
1974) found that in 33% of cases ofCIS and 50% of cases of mild/moderate dysplasia the 
counterpart specimen lacked the representative cells. 
Sampling errors in which there were no malignant cells or too few cells for examination may 
be attributed to the inadequacy of the instruments in sampling cells particularly lesions 
located more deeply within the endocervical canal. Traditionally the presence of endocervical 
cells is a sign of adequate sampling of the transformation zone. Spurrett et al.(Spurrett et al. 
1989) demonstrated marked variations in the differences in results for a simultaneous dual 
sampling technique using the Ayre's spatula and cytobrush. In 57 patients from a series of 
100, atypia was found on only one of the paired specimen; 22 cases of CIN or AIS present on 
one of the dual specimens, the transformation zone was either out ofreach of the Ayre's 
spatula or peripherally located on the ectocervix making it awkward for cytobrush sampling. 
(The location of the transformation zone was confirmed by colposcopy) These results were 
similar to a previous study by Boon et al (Boon et al. 1986) who also found an almost two-
fold increase in the lesions that were detected by the dual method of cytobrush and spatula 
compared to spatula alone. Use of the cervibroom in the latter study resulted in a reduced 
sensitivity compared to brush and spatula in diagnosing premalignant lesions. Barton et 
al.(Barton et al. 1989) in a small sample of 47 women with histologically proven CIN showed 
differences in the lesions that were 'missed'. Compared to lesions that were picked up on 2 
consecutive smears 3 months apart, lesions that were detected on 1 smear and not the other 
were those that occupied a smaller portion of the transformation zone. 
Biological changes relating to age may contribute to the occurrence of false negative smears. 
The retraction of the transformation zone during menopause could make it slightly more 
difficult to reach by the current instrumentation. Studies looking at the interval cancer rate 
have found a larger proportion ofregistrations occurring in women <35. (Bain et al 1983, 
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Benoit et al.1984, Mitchell et al.1990) For studies used to derive a range for the false 
negative rate and from which population age group information was available, interval 
cancers occurred more frequently among young women under 35. (Shulman et al 1974, 
Paterson et al 1984) However the latter findings can also be explained if greater participation 
in screening tended to occur in the younger age group. 
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4.3 NEWER DIAGNOSTIC METHODS 
4.3.1 Slide preparation techniques 
Thin Prep Pap Test - (FDA approved) results in better quality slides as shown below due to 
the elimination of mucus and blood from the sample. Instead of the sample being smeared 
onto the slide after collection from the cervix it is rinsed into a vial of buffered preservative 
solution. In the laboratory the sample is homogenised and a representative sub-sample is 
collected on to a single use filter and transferred onto a glass slide which is stained by the 
routine staining techniques. 
1. Dispersion 2. Cell Collection 3. Cell Transfer 
Fig.4.1 Preparation of a thin prep 
Recent clinical studies using this method have shown an increase of over 50% in detection of 
high and low grade lesions, which is greater than previous studies (see table 4 in appendix 4 
for a collation of studies comparing thin-prep and conventional methods), and a reduction of 
more than 50% of inadequate smears and lowering the number ofboderline cases diagnosed 
as ASCUS/ AGUS.(Papillo et al.1998, Bolick et al.1998) In two studies for which biopsy 
proven sensitivity and specificity measures were available thin prep resulted in a greater 
accuracy detecting low grade and high grade lesions compared to conventional smears. 
Sensitivity was 95.2%, specificity was 58%, positive predictive value 88.8% for thin prep; 
sensitivity 85%, specificity 36.3% and positive predictive value 80% for conventional smears 
of low grade and high grade lesions.(Bolick et al. 1998) Sensitivity 80. 7% for thins prep 
compared to 72.2% for conventional cytology. (Papilla et al.1998) 
, a . 
Fig. 4.2 (A) normal slide (B) thin prep showing much clearer image of cells 
Cytorich - is another method similar to the above, where cells are rinsed from a collection 
device into a preservative solution and a density gradient is used to prepare a thin layer of 
cells on a slide. AutoCyte-Prep (formerly known as CytoRich) is the advancement on 
cytorich. 
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See table 4 in appendix 4 for a collation of studies referring to an increased detection rate of 
abnormalities for both methods. (7-16% increased detection of abnormalities) The 
improvements in the detection of abnormal cells on smears should be viewed in the context of 
the background figure for the prevalence of abnormalities - approximately 5% quoted from 
the previous chapter. Therefore these newer slide preparation techniques may confer only a 
slight increase in the abnormalities that are detected thus a reduction to the numbers of false-
negatives. Reductions in the number of false positives (a positive test in the absence of 
disease see table 5.1 and 5.2) may occur ifthere was a tendency to overdiagnose boderline 
lesions. 
4.3.2 Image analysis devices 
Autocyte screen, Autopap and Papnet (the latter two are FDA approved) are automated 
devices with high degrees of sensitivity in detecting abnormal cells. These digital systems are 
equipped with powerful magnification systems that enable them to identify abnormal cells. 
The exact location of the abnormal cluster of cells is recorded and presented to lab staff for 
viewing as a high resolution image on a large-screen. These techniques confer the advantage 
of reducing false negatives (Halford et al. 1997) as well as a small reduction in the time 
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It is not the purpose of this dissertation to examine all the sensitivity and specificity testing 
that has culminated in FDA approval of these devices, however a few points will be noted. 
Autopap was approved on the basis of clinical studies on around 30,000 slides from six sites 
around the U.S. and Canada. Clinical studies evaluating the reduction of false negative rates 
showed an overall 50% reduction for low grade lesions and a 60% reduction in false negatives 
occurring in the diagnosis of high grade lesions. Large multi center sensitivity studies on 
archives of several thousands of slides for sensitivity, yielded 60% for LSIL and 80% for 
HSIL with test reproducibility of 100%. (Patten et al. 1998) 
Studies on Papnet have shown this to have a greater sensitivity ranging from 84-99% across 
numerous independent tests, (see table 5 in appendix 4) for detection of significant atypia, 
SIL and malignancy.(Mango 1998) However lower thresholds for determining sensitivities in 
the latter studies favor the higher sensitivities obtained for Papnet testing. The most recent 
studies confirming previous findings, correctly identify abnormal smears in 99%+ of biopsy-
proven cases (Jenny et al. 1997) and 89%+ of smears retrieved from an archive oflaboratory 
files. (Michelow et al. 1997) The device has also been shown to be useful in 'difficult' 
smears either due to a poverty of abnormal cells in the specimen, sub-optimal specimens or 
difficulties in observer interpretation (Doomewaard et al. 1997, Halford et al. 1997) with a 
high degree ofreproducibility. (Jenny et al. 1997, Mitchell and Medley 1998) An attempt to 
assess positive predictive value (PPV) through biopsy confirmation of lesions have been a 
little disappointing so far in at least 1 study where the PPV was 54% high grade lesions and 
32% for low grade lesions. 
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Table 4.1 validity of different techniques in evaluating smears 
Number of sensitivity specificity PPV 
smears 
Thin prep 
Bolick et al. 1998) 
SIL (using a 
95.2% 58% threshold of LSIL 54 88.8% 
of higher for +ve 
test) 
Papillo et al. 1998 
80.7% SIL (using LSIL as 140 
the threshold for a 
+ve smear) 
Auto pap 
Patten et al. 1998 
CAS trial (LSIL) 
2584 60% (HSIL) 
HSS trial (LSIL) 80.2% 
(HSIL) 3589 60.9% 
82.1% 
Papnet 
Jenny et al. 1997 
516 99.2% (Pre-malignant+ 
malignant lesions 
usingASCUS 
threshold for +ve) 
Michelow et 





Mitchell and 54%, 32% 
Medley 1998 20,000 













Cervical cancer is a significant health problem (as described in chapter 1 and 3) that can be 
ameliorated by screening. This is possible due to aspects relating to the natural history, 
detection and treatment policies of early and latent disease which have been covered in 
chapters 2 and 4. Overseas data providing evidence of the effectiveness of screening will be 
reviewed in section 5.3. In light of the huge successes ethical consideration must over-ride 
economic considerations in the provision of screening , however costs at the margin must also 
be considered and this will be discussed in section 5.5. The smear itself is relatively 
inexpensive to administer and can be done quickly with minimal discomfort. Issues related to 
the acceptability of the test will be referred to in section 5.4. The utility ofHPV screening 
will be considered in section 5.6. Epidemiological measures of test validity that inform 
decision-makers as to the suitability of the test for screening will now be considered. 
5.1 PRINCIPLES OF SCREENING 
Screening is dependent on the presence of a preclinical disease phase and an understanding on 
its natural history. The disease that is being prevented should have serious consequences so 
that prevention is desirable to avoid the adverse health results of the disease. Screening is 
also dependent on the presence of adequate services that can deal with early disease and treat 
the condition. The screening test should be acceptable to the screened population and easy 
and effective to administer. There should be an agreed policy on whom to treat and treatment 
should be acceptable to patients. The cost of case-finding should be economically balanced in 
relation to possible expenditure on medical care as a whole. Cost-effectiveness is also 
dependent on the prevalence of preclinical disease, with a higher prevalence yielding more 
cost-effective results. Case-finding should be a continuing process. (Wilson and Jungner 
1968) Screening for cervical cancer fulfills all the latter criteria. 
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Elements of the screening test that provide measures of validity are those of sensitivity and 
specificity. The ability of the test to correctly identify those that have the disease in the 
population refers to the sensitivity of the test; the ability of the test to correctly identify those 
without disease refers to the specificity. The positive predictive value (PPV) of the test is the 
probability of having disease once the test is positive. This is partially dependent on the 
specificity, as large numbers of false positives yield a low PPV. The characteristics of the 
population to which the screening test is applicable to will also influence the PPV as shown in 
table 5 .1. The PPV increases with the prevalence of preclinical diesease. An analogous 
concept is the PV (predictive value) negative which is the probability of an individual being 
disease free if the test is negative. The higher the sensitivity the less likely it will be that a 
negative test will harbor disease. 
Table 5.1 hypothetical situation of 1.0% prevalence of disease, 90% se1;1sitivity and 95% specificity 
Disease present Disease absent total 
+ve screening test 9 49.5 58.5 
-ve screening test 1 940.5 941.5 
total 10 990 1000 
Sensitivity 9/10=90% 
Specificity 940.5/990=95% 
PPV 9/58.5 = 15% 
Table 5.2 hypothetical situation of 5.0% prevalence, 90% sensitivity, 95% specificity 
Disease present Disease absent total 
+ve screening test 45 47.5 92.5 
-ve screening test 5 902.5 907.5 


























5.2 VALIDITY OF THE SCREENING TEST 
Chapter 4 has already alluded to the problems of determining false negatives which influence 
the sensitivity. Studies referred to in this section are those from which biopsy proven results 
were used to determine sensitivity and specificity. One study used a large computerized 
database of 748, 871 smears over a ten year period in Germany to calculate sensitivity, 
specificity and the positive predictive value. (Soost et al. 1991) Inclusion criteria for 
validation of results was rigorous with histological examination performed on almost all 
positive findings within 1 year of the smear diagnosis. Negative cytology was validated by 2 
subsequent smears within 3 years. If both smears were negative it was taken that the initial 
diagnosis of a negative smear was correct. Follow-up for severe dysplasia was 75% and mild-
moderate lesions - 28%. A second study used to establish the validity of cervical screening is 
based on a population screening program in one region of the Netherlands where screening 
programs have been operating in several regions since 1976. (Van der Graaf et al. 1987) 
Criteria for histological follow-up was based on a finding of severe dysplasia or worse. 
Attendance rate for the program was between 67-74%. Follow-up rates of all grades of 
dysplasia was 90% where women with milder grades of dysplasia that did not warrant 
colposcopy had repeat smears in 3-6 months. False negatives for both studies were 
determined by retrospective review of smears for women diagnosed with severe dysplasia or 
cancer. 
5.2.1 Sensitivity 
For the Dutch population screening program sensitivity was calculated at 24, 36 and 48 
months - the follow-up period. When only invasive cancers and carcinoma in situ were 
considered sensitivity was 95%, 92% and 89% for the follow-up periods. For all epithelial 
abnormalities (severe dysplasia, carcinoma in situ and invasive cancer) sensitivity was 
calculated to be 94%, 89%, 83%. 
Sensitivity in the German study was lower for dysplasia than for cancer. For mild and 
moderate dysplasia this was 78.1 %; for carcinoma in situ and severe dysplasia- 81.4% and 





Specificity for the German study was 99.4% and 99.9% for the Dutch study 
5.2.3 Positive Predictive Value 
Positive predictive value varied according to the degree of dysplasia with the lower degrees of 
dysplasia yielding less reliable results from cytology. For the German study the predictive 
value of a smear for mild to moderate dysplasia was 73.4%; severe dysplasia and carcinoma 
in situ 90.6%, 94.5% for carcinoma in situ or microinvasive carcinoma; 95.5% for an initial 
diagnosis of invasive carcinoma. The Dutch Study calculated PPV's for the first screening 
round followed by the second screening round at 3 years after the first smear. PPV's were 
82% and 67% respectively for all grades of epithelial abnormality. The authors attribute the 
lower PPV in the second screening round to a lower prevalence of disease. 
The lower PPV for mild-moderate grades of dysplasia may be explained by the greater 
tendency of lower grades of dysplasia to regress than for severe dysplasia or carcinoma. This 
would only be an issue if follow-up periods between cytology and histology were long. 
Interpretation of initial cytology may have erred on the side of a more severe grading for all 
grades of abnormality as the consequences of under-reporting would have been 'costly' for 
clinicians and subjects. 
Table 5.3 sensitivity, specificity, PPV of cervical smears 
Van der Graaf et Soost et al. 1991 
al.1987 
sensitivity 94% severe 78.1 % mild-mod 
dysplasia 81.4% severe 
89% CIS dysplasia/CIS 
83% invasive 82.3% invasive 
carcmoma carcmoma 
specificity 99.9% 94.5% 
PPV 82% 1st screen 73.4% mild-mod 
67% 2nd screen 90.6% severe 







5.3 EFFECTIVENESS OF SCREENING 
The most definitive way to evaluate the effectiveness of a cervical screening program is by 
means of a randomized controlled trial comparing the cervical cancer mortality of those 
randomized to be offered screening compared to the mortality experience of women without 
screening. Given the large reduction in mortality achieved by the introduction of screening 
programs in Europe and North America demonstrated in observational studies, this type of 
trial is not ethical. 
Trends in the international mortality and incidence of cervical cancer have been described in 
section 1.5. and 3.3. These trends document declining rates in mortality and incidence that 
correlate with the introduction of screening. However comparison is limited by the 
considerable variation in screening policy as well as coverage. In England, the 
implementation of a national call and recall system in 1988 has resulted in increases in the 
registration of in situ disease paralleling the increase in the number of smears. The incidence 
of invasive disease remained stable through the 80's but declined after the commencement of 
the new system resulting in a 35% reduction (since the 80's) of disease by 1995. (Quinn et al. 
1999) This was achieved by a doubling of the target group reached by screening prior to the 
introduction of the register, to include 85% of the population by 1994. (Quinn et al 1999) 
This has been mirrored by Scottish trends for the same period, where similar magnitudes of 
reductions in mortality and incidence of cervical cancer took place with the introduction of a 
more systematized methods for screening with increased coverage of the population. (Walker 
et al. 1998) 
Laara et al. (Laara et al. 1987) showed that the declines in mortality from cervical cancer 
experienced by Norwegian women where screening was not as extensive, was lower than 
other parts of Scandinavia - Denmark, Sweden and Finland, and Iceland where there were 














Agegroup · . / 
and period Denmark Finland Iceland Not:Wlly Sweden 
2Q-29yr 
1963-o7 H O·I O·O 0·5 0·4 
1978-82 M 0·2 . O·O 0·9 0.·6 
Oiange(%) 0 +150 0 ·+64 +60 
30-,,,39yr 
1963-67 13·3 3·3 7·0 6·5 6·3 
1978-82 s-i· .0·9 O·O :H. 2·5 
Change(%) -61 -72 -100 -48 -59 
4Q-49yr 
1963-67 .. 29·3 11'4 24·2 12·8 14.:5 
1978-82 13·7 2'6 5.·5 .9·9 4,9 
Change(%) .,..53 -77 7'77 -23 -'66 
50-59yr 
1963-67 29·8 17-7 17·2 16-1 16-0 
1978-82 22·2 7·0 5·8 15;7 9·5 
Qi;mge(%) -26 -60 -66 -2 -40 
60-o9yr 
·16'5 1963-o7 28·9 19·0 22·0 14'4 
1.978:-82 29·1 12·9 7-5 18·8 15·4 
Change(%) +I -32 -66 +14 +7 
70-79yr 
196:}-67 29•1 22·7 i4.·5 20-4 15·9 
1978-82· .30·0 16-8 10·8 22·0 15·9 
Change.(%) +3 -26 ""25 +ff 0 
.. 
Table 5.4 Mortality rates s(per 100,000 years) for cervical cancer in 1963-67 and 1978-82 and% rate of change 
between these two periods Laara et al 1987 
A number of case-control studies have demonstrated the effectiveness of screening by 
comparison of the screening history of women with cancer and those without. An increased 
risk of cancer occurred amongst women with no screening history. (Clarke et al.1979, 
Aristizabal et al.1984, La Vecchia et al.1984, Van der Graaf et al.1988) For women whose 
last normal smear was within 5 years, the risk of developing cancer was lower than those 
women in whom the length of interval since the last normal smear was greater than 5 years. 
(La Vecchia et al.1984,Van der Graaf et al. 1988) 
The inherent problem in case-control studies is that of selection bias. Women who participate 
in screening may be more health-conscious or healthier therefore having a lower risk of 
cervical cancer. Disproportionate responses among cases and controls may also bias results. 
A high non-participation rate amongst cases due to death, morbidity or inability to trace 
women occurred in studies by Clarke et al., Aristizabal et al. and Van der Graaf et al. (Clarke 
et al. 1979,Aristizibal et al. 1984, Van der Graaf et al. 1988) Participation rates among 
controls were better. Since the screening history of the non-participants are unknown, the 
calculated odds ratios may be an under estimate or an overestimate. 
Non-participation rates were negligible in La Vecchia et al.'s study as this was conducted 







Control group populations derived from such settings introduce bias into the study as they 
may not be representative of the general population in terms of health and screening activity. 
Thus generalizing to the greater population may not be valid. The 'healthy volunteer' effect 
operating to produce selection bias is highlighted in Aristizabal's study. (Aristizabal et al. 
1984) Two control groups - one from a local health center the other from the neighborhood 
were used for comparison alongside cases. In doing so there was some implicit matching by 
socioeconomic status as neighborhood controls were likely to be similar in the latter aspect to 
the cases to which they were matched. The assumption here was that the health center sample 
was expected to have a higher utilization rate of health services than a random selection from 
the neighborhood. Accordingly the bias towards an exaggerated health effect is displayed in 
table 5.2 showing higher relative risk of cancer in women without a previous smear history 
amongst the health center controls compared to neighborhood controls. 
Classification of disease in different studies also reduces inter-study comparability. In the 
study by La Vecchia (La Vecchia et al. 1984), inclusion of microinvasive disease in case data 
may have resulted in an underestimate of the risk reduction associated with screening. Micro-
invasive disease may be conceptualized within the spectrum of pre-clinical disease as women 
are asymptomatic in this stage. The inclusion of this in the disease category results in length 
bias which contributes to an over-representation of disease among screen detected cases with 
a long pre-clinical phase. (Hennekens 1997) 
Cases and controls were matched by age+/- marital status. Some studies reported variations 
between cases and controls with regards to known risk factors such as the larger number of 
sexual partners and early age first intercourse occurring more frequently in cases. Bias from 
confounding factors was dealt with in all studies by incorporating risk factors such as age, 
socioeconomic status, number of partners, oral contraceptive use .. .in a multivariate analysis 
or else by stratification ofrisk factors. Clarke (Clarke et al. 1979) performed a stratified 
analysis for the variables of age, income and education which differed between cases and 
controls. Both methods resulted in little alteration to the protective effect conferred by 
screenmg. 
Odds ratios listed in the table below confer either a risk reduction associated with screening or 
and increased risk when women did not have a screening smear. The large differences in the 
magnitude of increased risk associated with not being screened in studies by Clarke, 
Aristizibal and may be attributed to the variations in incidence of cervical cancer. The South 
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American continent where Aristizibal' s study was conducted have a much higher incidence of 
cervical cancer (Parkin et al. 1994) compared to the North American continent where the 
study by Clarke took place. 
Table 5.5 Risk estimates for cervical cancer according to screening history 
Study group 
Clarke et al. 1979 
Aristizabal et al. 1984 
La Vecchia et al. 1984 
Van der Graaf et al. 1988 
cases/controls OR+/- 95% confidence 
intervals for risk of cancer 
212 / 1060 2.7 (2.0-3.7) p<0.0001 for 
women not screened 
compared to women who 
were ever screened 
204/576 health center control 23.9 for women not screened 





Exact numbers not stated 
9.9 for women not screened 
compared with ever screened 
( confidence intervals and p 
values not stated) 
0.56 (0.29-1.08) 1 smear 
compared with never 
screened 
0.19 (0.10-0.35) 2 or more 
smears compared with never 
screened women p <0.001 
0.22 (0.07-.69)ever screened 
compared to never screened 
women 
0.18 (0.05-0.62) last smear 2-
5yrs compared with never 
screened (p values not stated) 
0.33 (0.09-0. l .02)smear>5yr 
compared with never 
screened 
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5.4 REQUIREMENTS OF A SCREENING PROGRAM/ OPERATION OF THE NEW 
ZEALAND NATIONAL CERVICAL SCREENING PROGRAM (NCSP) 
• A smear register whether part of a centrally organized program or a primary care setting 
is a means of identifying the target population from records of date of birth or age. This 
may contain a database for laboratory information on women's smears. 
• Trained staff in taking smears and performing pelvic examinations. 
• Relationship with the laboratory includes transport and delivery of slides as well as 
liasing for communicating information about results. 
• Relationship with the treating institution for the follow-up and treatment of women with 
abnormal smears. 
• Ensuring the target group is screened by means of personal invitation, opportunistic 
screening of target women or use in special health care settings such as family planning 
clinics. 
• Recording and reporting systems for reporting results and patient follow-up. 
• Information flow through to women about their results 
(Miller 1992) 
The centralized system in New Zealand has been managed by the Health Funding Authority 
since 1998. The new administrators have not formalized policy concerning the administration 
and organization of the NCSP therefore the status quo for policy is that of the previous 
coordinators - the Ministry of Health. 
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To clinic ~s 
instructed 







Patient referred for 
more comple1< 
· treatment. 
Summary of findings 
and biopsy report 
Summary.of findings, 
treatmerit•and outcome 
Patient referred back· 
for follow-up 
Biopsy report and Biopsyspecimen. and 
recommendations full clinical fir1dings 






reports and full 
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Histopathology Smear report and 
report {slides) screening summary 
Record of clinical 
findings, treatment 
and outcome 
~--~, Central cytq~hology laboratory 
(Cytopathologist-in~chai'ge) 1-----' Referral Hospital 
Record of clinical 
rinding, treaiment 
and outcome il'h'.:J.tl:~!H 
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-' taking smears 
- informing patients of follow-up instructio•u 
and ensuring. compliance 
Referral Hospital . 
- assesssment and treatment of referred patients 
- over.all direction and management 9Pprogramme 
- irlfOrmatiOrl from treatmenLcentres,J1ospitals, 
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-·interpretation andrep~rti'19 of smears 
- patients' records ("ceritra'I registry") 
-, monitoring of follow-:up 
Histopathology laboratory 
Respomible for : 
- interpretation of biopsy specimens and for reporting results 
Fig. 5.1 Cervical cancer information flow chart WHO 1988 
5.4.1 Information systems for cervical cancer screening 
System recommendations described here are taken from a World Health Organization 
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guideline based on Canadian findings. A good information system facilitates the organization 
and running of a screening program. Essential information required on such a system 
includes: 
• the target population 
• a register of all smears identifying whether smears are first or repeat smears 
• a separate register of abnormalities and follow-up 
• correct classification of pre-cancerous lesions, cancerous lesions and deaths 
• possible linkage to other registries such as the cancer registry. 
(Miller 1992) 
The NCSP fulfills these criteria.(except for the absence oflinks to any other registry) The 
centrally based register also facilitates communication to women informing them of their 
presence on such a register as well as smear results and an opportunity to update current 
personal details. 
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Annual statistical reports derived from the NCSP register facilitate evaluation of the program. 
Information on enrolments on the NCSP allows evaluation of the extent of coverage of the 
target population. Smear volumes, screening frequency, adequacy of the smear, histology and 
quality of the cytology reports are also examined. 
Provision for confidentiality of information for the NCSP has been made by the following 
protocols: I.Health Act 1956 2.NCSR National Security Protocol 3.Health Regulations Act 
1995 protects access to Maori women's data 4.Access to Pacific Island Women's data is 
determined by the Interim Pacific Data Management Group 5.0fficial Information Act 1987 
6.Privacy Act 1993. 
5.4.2 Quality control issues for the Laboratory 
The term 'quality control' in relation to cervical screening laboratory techniques has become 
as pathognomic to cytology as 'QALY's' to economic evaluations. An I.A.C. (International 
Academy of Cytologists) task force review of the issue concluded the need for nation specific 
standards to take into account the sub specialty areas within cervical screening. (I.A.C. 1998) 
Some of the methods referred to include: calculation of the fraction of smears that are false-
negatives, peer review, personnel standards, laboratory accreditation, targeted re-screening, 
cytohistologic correlation, external performance assessment. While no one method was 
endorsed there was approval given for an adoption of a range of methods to be employed 
when implementing quality-control measures. Acknowledgement for cost-containment was 
voiced by defining standards of care within resource constraints. The rising problem of 
quality-control measures for emerging technology was raised, listing specific options for 
assessment of the newer digital image screening processes. (ie. Papnet) I.A.C. also identified 
issues of workload minimums quoting data from the College of American Pathologists as 
having documented higher error rates amongst laboratories screening less than 5000 cytology 
specimens per year with no screening cytotechnologist. 
Current national policy requires quality control measures for laboratories to provide an 
efficient and accurate service for processing and examining smears. Histology and cytology 
results are forwarded to the national register. Laboratories must be accredited with IANZ 
(International Accreditation New Zealand) in order to be eligible for reimbursement for 
reading smears. The opening words of the document produced by the latter organization state 
that requirements are 'general' and include measures for ensuring adequate documentation, 
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suitable external environment of work, handling of specimens, complaints procedures ... with a 
provision that labs should be part of an additional external quality assurance program. (IANZ 
1998) For most laboratories in New Zealand this process of an external quality assurance 
standard comes by way of a program run by the Royal Australasian College of Pathologists. 
(personal communication Dr David Roche Southern Community Laboratories) Batches of 
'test' slides are sent out to laboratories for reading on a routine basis. 
Internal quality control programs exist in most laboratories across New Zealand and vary in 
their methodologies of assessing staff performance. These include a variety of measures such 
as rescreening a variable percentages of slides, review of abnormal slides, monitoring staff 
performances. (personal communications with Dr David Roche of Southern Community 
Laboratories, Harold Neal Quality Control Manager Canterbury Health Laboratories) 
5.4.3 Health Promotion and Education Strategies for screening 
Based on the MOH 1996 protocol, basic strategies for cervical screening are consistent with 
the Ottawa Charter for Health Promotion. These include promotion of healthy public policy, 
community action, creating supportive environments, developing personal skills and re-
orienting the health services. Provision is made for the training of educators for Maori and 
Pacific Island women in the area of cervical screening. 
Smear taking is an embarrassing, uncomfortable procedure. Given there is no alternative to 
the current procedure of obtaining cervical cells, women's attitudes are an important area in 
which health promotion has a big part to play in the success of screening. Thus health 
education portraying the benefits of screening as well as a realistic understanding of the 
limitations of testing, should be designed to reach women particularly those occupying the 
lower socioeconomic groups. Current methodologies include a national television campaign 
and written information that is available and displayed in routine health care settings such as 
general practices, CHE's, family planning clinic. A large responsibility also rests with the 
pro-active nature of staff in the medical setting in which health care is demanded. At an 
administrative level, the provision of a financial remuneration for these specific services may 
serve as an incentive for doctors in primary care settings to be slightly more pro-active in their 
approach to screening. (Krasnik et al. 1990) Making available choices for women in being 
able to select the health care setting and provider/smear-taker may ameliorate some of the 
negative attitudes towards screening. 
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Socioeconomic differentials have already been discussed in chapter 1. There is the potential 
problem of a variation in physician encounters for women according to their social class. 
(Katz et al. 1994) This situation may arise when the type of problem necessitating medical 
consultation warrants other forms of more urgent health care that takes priority over 
preventative care. In a study on breast cancer utilization by Harper (Harper 1993) a recurrent 
statement by women in the low-income groups studied was that 'doctor doesn't tell me' 
suggesting a prejudicial treatment by the medical profession of such women. 
Health promotion among the elderly is an issue because of the persistence of late stage disease 
among older women as discussed in section 5 .2. This is exhibited by the lower uptake of 
screening in older women in studies by Cohen et al. (Cohen et al. 1989) and Orbell et al. 
(Orbell et al. 1995) Enrolments on the NCSR by age show a persistence of age differentials 
with older women belonging to the 60-70 year age group having lower levels of uptake of 
screening than those under 60. 
Non-financial costs such as time spent travelling to the doctor seemed to be reflected in a 
survey of Canadian women in which unscreened women were more likely to be rural 
dwellers. (Cohen et al. 1989) Over a range of questions assessing practical difficulties in 
Orbell et al.'s study (Orbell et al. 1995) having dependents was the only factor contributing 
significantly to differences amongst screened and unscreened women. Unscreened women 
more likely to have dependents to care for. Practical difficulties such as difficulties with 
transport, other medical problems etc. were not associated with social class. (Orbell et al. 
1995) 
5.4.4 Treaty considerations 
Operation of Treaty of Waitangi principles is three-fold in the NCSP: l.A commitment to 
improving health of Maori; 2. Consultation in the development and management of cervical 
screening; 3. Protection of information of the results on the smears of Maori women. 
The incidence and mortality rates amongst Maori for cervical cancer has been higher than in 
the European population. (Hauora 1989, Ministry of Health 1995) Cervical screening is in 
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accordance with Crown's Maori policy objectives set out in Whaia te ora mote iwi and the 
Treaty acknowledging the need for screening to be conducted in a culturally appropriate way 
with an aim to reducing disparities. As well as consultation of Maori in the policy process of 
screening there are Maori screening coordinators, educators and smear-takers. 
Data relating to the screening results for Maori women is not readily available and is stored 
separately. This information is under the official guardianship of The National Kaitiaki 
Group. 
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5.5 SCREENING INTERVALS AND COST-EFFECTIVENESS 
Commencement of screening from the age of 20 (National Cervical Screening Guidelines 
1998) in New Zealand and several overseas programs is consistent with the epidemiology as 
described in chapters 1- 3; that of an extremely low incidence of cervical cancer around this 
age as well as the high incidence of preclinical disease in this around this age. The lower 
incidence of preclinical disease in the age range above 35 has led to a call by task forces in 
Canada for less frequent screening of this age group. (Miller et al. 1991) The Canadians and 
Americans also recommend at least two (three by the American Cancer Society) consecutive 
negative smears at the commencement of screening because of the significant false-negative 
rate. (Miller et al 1991, http://www.cancer.org) 
Screening intervals can be inferred from previously successful programs such as those of the 
Nordic countries which achieved marked reductions in mortality and incidence of cervical 
cancer based on intervals of2-5 years. (Laara et al 1987) Work by the International Agency 
for Research on Cancer has demonstrated similar results. A collation of the results of several 
large screening programs conducted in the 1960's and 70's shown in table 5.5 show the 
greatest impact on mortality is for screening intervals of 1-3 years. 
Table 5.6 Reduction of cumulative rate of invasive cervical cancer for the age group 35-64 years with different 
screening :frequencies WHO 1988 adapted from Day N.E 'The epidemiological basis for evaluating different 




















The appropriate screening interval will be a function of the natural history of disease, the false 
negative rate and the incidence of invasive disease, the financial costs involved in screening 
and the capacity of the medical infrastructure to deal with screening. Several authors have 
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generated models using this type of data to demonstrate the variations to cost-effectiveness of 
a program as screening intervals are reduced. The crucial factor is the marginal cost - the 
increase in cost for each additional input of resources. Two such studies on two different 
hypothetical populations will be used here to show the most efficient and cost-effective 
screening interval is a 3-5 yearly interval. 
In a cost-effectiveness study by Fah et al for a hypothetical elderly population aged 65 and 
upwards the most cost-effective screening interval was a 5 yearly interval. (Fah et al. 1992) 
Whilst more life-years are gained by reducing the interval , reducing the screening interval 
from 3 yearly to yearly results in a huge increase of the incremental cost producing a 6 fold 
increase in costs from 41 million to 269 million dollars. The incremental increase in costs is 
much less (10 million dollars) switching from a screening interval of 5 yearly to 3 yearly. (see 
table 5.6) When this is converted to a cost effectiveness ratio by placing a dollar value on the 
lives saved, once again the ratios reflect the hyperbolic nature of the incremental costs. Thus 
the incremental cost per life year saved for yearly screening is 33, 000 as opposed to 6000 
dollars for 3 yearly screening. The lower ratio being the more economically desirable and 
efficient situation. 
Table 5.7 Cost effectiveness of screening under alternative screening intervals (Fah et al 1992) 
Screening Discounted Cost Cost- (Cost per 
schedule life years (millions) effective year of life 
(lOOO's) ratio for gained) 
Total Increment Total Increment screenmg Increment 
US$ US$ 
No 11 383.1 217.79 
Screening 
Once at 65 11 397.5 14.4 241.78 23.99 1666 1666 
Every 5yrs 11 419.3 21.8 273.46 31.68 1453 1543 
Every 3yrs 11426.3 7.0 315.15 41.69 5956 5956 
Every year 11 433.1 6.8 585.06 269.91 33693 33693 
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Eddy (Eddy 1990) using a similar model to Fah et al. for a 20 year old woman screened until 
75, also shows the huge rises in the marginal costs of screening yearly and 2 yearly as 
opposed to less frequent screening intervals.(table 5.7) This model demonstrates: a decrease 
in probability of developing invasive cancer which shows little difference between screening 
intervals with the exception of annual screening; a decrease in lifetime probability of death 
once again showing only slight variation between screening intervals; a huge increase in the 
marginal costs that occur with the increased screening with only a slight increase in life 
expectancy which would economically justify a three yearly interval. 
Table 5.8 Estimated outcomes of cervical cancer screening for and average risk assymptomatic 20-yr old 
woman screened from 20-74 (Eddy 1990) 
Estimated Every Every 4 annual Every2 3 annual Every year 
Outcome 4 years 3 years -ve smears years -ve smears 
then 3 yrly then 2 yrly 





Decrease in 104.3 105.2 105.4 106.7 106.8 108.5 




Increase in life 
93.8 95.4 95.7 96.9 97 98.9 expectancy 
(years) 
Net costs US$ 264 355 467 439 597 1093 
Marginal cost 10 000 182 681 336 2 628 000 >1000000 >1000000 
per year oflife 
528 
ex:eectancl 
Like all models, they are only as good as the assumptions made in generating them. Both 
authors have used age-specific incident rates. As discussed in chapter 1 and chapter 3 there is 
a birth cohort effect with subsequent cohorts having lower risks. This was taken into account 
in Eddy's modelling result but not by Fah et al. The false-negative rate used by Eddy et al 
was 3% - a figure that is hugely at odds with some of the findings referred to in studies in 
chapter 4. Economic analyses usually seek to deal with these uncertainties by a 'sensitivity 
analysis' in which one variable at a time is changed and observing the changes in the final 
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analysis. (Donaldson 1990) If there is little difference to the final result then the analysis is 
considered to be robust. Increases in the false-negative rate of Eddy's model could produce a 
much higher marginal costs particularly for the smaller screening intervals. Fah et al. 
accounting for possible variations in sensitivity and specificity notes that a reduced sensitivity 
from 75% to 50% and specificity from 95% to 87% results in a $7000 increase to the cost per 
life year saved. Assumptions to disease progression rates are another factor with the ability to 
heavily influence results. Fah et al assumed a 0% disease regression rate for CIS and CIN 3 
in the model which is clearly not the case as outlined in chapter 2. If some degree of 
regression is assumed, then the cost side of the equation would be an overestimate except that 
all detectable high grade lesions tend to be treated rather than observe a period of 'watch and 
wait'. These analyses support a three yearly interval for screening however more sensitivity 
analyses should have been undertaken varying a number of parameters to ascertain the effect 




5.6 SCREENING FOR HPV 
5.6.1 Detecting HPV 
Techniques for detecting HPV involve current knowledge that has enabled sequencing of 
HPV DNA which can be detected by the polymerase chain reaction (PCR) the method used 
by ESR, and a hybridization capture technique. (HCT) Both these methods reliably detect 
viral DNA. (http://horizonpress.com/pcr/ http://experts.co.uk/ 
http://digene.com/customer/techup/hcs tech.html, Park et al.1995) Previous DNA detection 
methods that have been superceded by the latter techniques were those of the Western and 
Southern Blot assays, in situ hybridization and Virapap. 
PCR: From a known portion of the sequence ofHPV DNA, primers are formed consisting of 
single strands of the sequence which are then amplified to produce large quantities of a 
particular sequence. An excess of primer is placed with a sample obtained from the cervix in 
a solution denaturing the DNA which bind to single strands of the primer. By means of a 
polymerase enzyme the entire DNA sequence is formed and identified by means of binding 
proteins. (see figure 5.2) 
HCT: An RNA probe binds to the target nucleic acid in an appropriate environment creating 
an RNA:DNA hybrid. This is captured by a specific antibody reaction and detected by 
immunofluorescent techniques. 
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Another round: DNA is 
1' 
DNA is denatured, Primers attach 
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5. 
Continued rounds of amplification swiftly produce 
large numbers of identical fragments. Each 
fragment contains the DNA region of interest. 
Fig. 5.2 PCR method 
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In the absence of a vaccine or treatment for HPV, the aim of screening for this virus would be 
to reduce the number of false negatives associated with the pap smear. HPV screening should 
also confer some predictive value for developing cancer since it is known that certain HPV 
types are associated with cancer. However not enough is known about the natural history of 
HPV infection to apply this screening criterion to HPV testing. Thus one of the goals of 
HPV screening could be to detect high risk types in smears that are equivocal in their 
diagnosis - ASCUS/ AGUS or inadequate in terms of the sample. From the limited body of 
available data there is evidence of improved sensitivity detecting SIL's when HPV testing is 
used alone or as an adjunct to the pap smear. (Cox et al. 1995, Hall et al. 1996, Ferris et al. 
1998) 
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The latter studies have used the method of hybrid capture for detection ofHPV. The numbers 
of participants in studies ranged from 151 women in the study by Hall (Hall et al. 1996) to 
242 in the study by Ferris (Ferris et al. 1998) with the majority of women falling into the age 
range of20-30 years old. Study participants' presenting diagnosis was that of ASCUS or 
LSIL from an initial smear. This was followed by repeat cytology, HPV testing and 
histological verification. 
The improvement in sensitivity in Hall's study (Hall et al.1996) from 87% to 93% for the 
hybrid capture technique is slight. In Ferris's results (Ferris et al. 1998) even though the 
sensitivity detection of a high grade lesion seems alarmingly low when LSIL is used as the 
lower threshold for determining an abnormality, sensitivity is very much greater when the 
lower threshold for determining further evaluation is reduced to ASCUS. The largest gains 
have been displayed in the study by Cox (Cox et al. 1995) with a 30% improvement in the 
detection of lesions when a combined technique of HPV testing and pap smear is used with 
compromises in the specificity of the test. 
The studies referred to in table 5.5 demonstrated large numbers of women with normal or 
equivocal cytological findings of ASCUS ( confirmed by biopsy) that were also HPV positive 
including high risk types. This is reflected by the lower specificity's associated with hybrid 
testing. It would be a dilemma for physicians and a waste of resources if they tried to identify 
women on the basis of a positive hybrid capture test and a normal pap smear (that was 
initially abnormal) given that the latter technique is sensitive in detecting abnormalities. 
Figure 5.3 demonstrates one method that has been successfully used in a clinic in Montreal to 
deal with this problem. 
In reality repeat testing is carried out on smears demonstrating initial abnormalities. The 
lower threshold for repeat cytology will determine the sensitivity of pap testing and 
ameliorate the effect of false negatives in pap smears. This is reflected in studies by Hall 
(Hall et al. 1996) and Ferris (Ferris et al. 1998) who obtained higher sensitivity estimates for 
pap testing alone hence smaller improvements for the dual technique. (The study by Ferris et 
al. 1998 shows no improvement in sensitivity for the dual technique compared to pap testing 
in isolation using a lower threshold of ASCUS for determination of sensitivity.) 
HPV testing for high-risk types as an adjunct for screening is a method employed by isolated 







histological examination for women with smears showing CIN 1 or CIN 2. 
(http://www.zytologie.de/hpv _ engl.htm) In Montreal HPV screening for high-risk types has 
been used successfully in triaging smears with a diagnosis of ASCUS; repeat pap testing that 
yields a result of ASCUS and tests positive for a high-risk type ofHPV will be followed-up 
by colposcopy whereas in the presence of only one of these tests being positive women are 
offered repeat cytological examination at a shortened interval. (Ferenczy et al. 1997) 
Table 5.9 validity of using HPV testing alone or as an adjunct to smear diagnosis 
Sensitivity % Specificity % Positive predictive 
value% 
Cox et al. 1995 ( cases 
ofhistologically proven 
CIN) 
Pap alone 60 77 44 
ASCUS or SIL 
diagnostic threshold 
Hybrid capture alone 86 71 47 
( all HPV types) 
Pap + hybrid capture 90 58 39 
( all HPV types) 
Hall et al. 1996(biopsy 
proven HSIL) 
87 Pap alone showing 
abnormal cytology 
hybrid capture for 
high risk HPV' s only 93 
Ferris et al. 
1998(biopsy proven 
HSIL's) 
Pap smear alone 70 44.7 7.4 
ASCUS lower 
threshold 
Pap smear alone 
LSIL lower threshold 20 85.5 8.0 
HPV high risk 50 66.7 8.6 
Pap smear and HPV 70 37.1 6.54 




































Fig. 5.3 Methodology for screening pathway used in Montreal 
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6 POSITIVE PREDICTIVE VALUE OF CYTOLOGY 
The positive predictive value (PPV) is a measure of what proportion of women with positive 
tests actually have the disease. For cervical cytology the cytological result is not merely 
positive or negative but encompasses a range of possibilities. The inter-relationships between 
the predictive value, sensitivity and specificity have already been described in chapter 5. The 
predictive value is a measure of the performance of the program, since low predictive values 
positive would mean that large numbers of women are unnecessarily followed-up and result in 
an inefficient use of health care resources and unnecessary anxiety for women. 
6.1 METHODOLOGY 
Information on cytology and histology relating to abnormal smears has been obtained from 
the National Cervical Screening Program Register. Results were available for the period July 
1993-December 1996 and have been grouped in ten year age groups except for the extremes 
of the age spectrum - <20 and >70 years old. Results from abnormal smears have been 
grouped according to the following categories:LSIL - low-grade squamous epithelial 
lesion;HSIL - high-grade squamous epithelial lesion which includes sqaumous invasive 
cancer and carcinoma-in-situ;AIS - adenocarcinoma in-situ;adenocarcinoma. Calculations of 
PPV exclude absent histology, inadequate specimens and ungraded results. (appendix 1 
contains all cytological and histological data) Ideally it would have been good to obtain the 
cytological result that most closely correlated with the histological diagnosis in the case of 
multiple abnormal smears, (since appropriate follow-up for an initial smear showing LSIL is 
to repeat the smear followed by colposcopy/biopsy for persisting abnormalities) however this 
was not possible, instead abnormal cytology relating to the first abnormal smear that might 
have led to further investigations has been used. Women have the option of withdrawing 
from the register resulting in further losses of information. Results are not inclusive of Maori 













































The range of possibilities for the predictive value of cytology is: 
histology 
cytology LSIL HSIL adenocarcinoma normal 
LSIL a b C d 
HSIL a b C d 
A low grade lesion (LSIL) on cytological diagnosis may have a predictive value of the latter: 
LSIL a/a+b+c+d; or the predictive of a high grade lesion (HSIL) will be b/a+b+c+d. The 
predictive value positive increases with the prevalence of preclinical disease in the population 
being screened and also as the specificity of the test increases. (see chapter 5) 
An alternative method for calculating the predictive value for LSIL would be to classify all 
lesions with a diagnosis ofLSIL or worse as a true positive result therefore the predictive 
value of a smear showing LSIL can be considered to be a+b+c/a+b+c+d; the predictive value 
for HSIL could also be calculated as b+c/a+b+c+d. In order to describe the exact level of 
match and describe category specific trends between the cytological diagnosis and 




Table 6.1 cytology, histology and ppv for abnormal smears 1993-1996 for New Zealand women <20->70: 
NSCP 
Under 20 
0 0 0 1 0 
0 2 614 324 54 994 
0% 0.2% 61.8% 32.6% 5.4% 
0 1 710 1677 311 2699 
0% 0.04% 26.3% 62.1% 11.5% 
20-29 
Adenocarcinoma 2 3 3 1 0 9 
V 22.2% 33.3% 33.3% 11.1% 0% 
2 8 9 4 3 26 
I 7.7% 30.8 34.6% 15.4% 11.5% \ 
( 7 47 5126 1268 271 6719 
! 
0.1% 0.7% 76.3% 18.9% 4% 
6 23 3290 5413 1269 10001 
V 0.06% 0.23% 32.9% 54.1% 12.7% 
1 
30-39 I 
Adenocarcinoma 7 4 6 1 1 19 
V 36.8% 21% 31.6% 5.2% 3% 
AIS 11 28 14 5 1 59 
V 18.6% 47.5% 23.7% 8.5% 1.7% 
16 56 3686 706 248 4712 
V 0.34% 1.2% 78.2% 15% 5.2% 
LSILC 9 26 1491 2980 1264 5770 
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40-49 
6 2 6 4 8 26 
23% 7.7% 23% 15.4% 30.8% 
AIS C 7 15 12 2 4 40 
17.5% 37.5% 30% 5% 10% 
15 23 1382 298 145 1863 
0.81% 1.23% 74.2% 16% 7.8% 
16 19 530 2050 1336 3951 
0.40% 0.48% 13.4% 51.9% 33.8% 
50-59 
5 0 4 4 11 24 
20.8% 0% 16.7% 16.7% 45.8% 
AIS C 5 5 2 2 2 16 
31.3% 31.3% 12.5% 12.5% 12.5% 
9 9 419 123 72 851 
1.4% 1.4% 66.2% 19.4% 11.3% 
7 2 148 640 570 6216 
0.51% 0.15% 10.8% 46.8% 41.7% 
60-69 
Adenocarcinoma 8 2 3 3 9 25 
Cytology 
POV 32% 8% 12% 12% 36% 
AIS Cytology 2 0 0 1 1 4 
50% 0% 0% 25% 25% 
HSIL Cytologv 6 6 240 49 34 449 
POV 1.8% 1.8% 71.6% 14.6% 10.1% 
LSIL Cytology 5 3 52 166 164 2241 
PPV 1.3% 0.77% 13.3% 42.6% 42.1% 
70+ 
Adenocarcinoma 13 1 3 0 6 23 
Cytology 
ppv 56.6% 4.3% 17.4% 0% 26.1% 
HSIL Cytology 9 0 86 8 16 119 
ppv 7.6% 0% 72.3% 6.7% 13.4% 
LSIL Cytology 7 2 17 22 39 87 
8.0% 2.2% 19.5% 25.3% 44.8% 
75 
For women under 20 the PPV for a correlation between an HSIL on cytology and HSIL on 
histology is 61.8%. For women between the ages of 20-49, the PPV for biopsy proven 
HSIL's from a cytological diagnosis of HSIL is 72-78%. The PPV for biopsy proven HSIL's 
from a cytological diagnosis of HSIL among women in the 50+ age group ranges from 66-
72%. Approximately 25% oflesions diagnosed as being HSIL from a smear did not have a 
histological diagnosis for correlation and was therefore excluded. 
For women under 20 the PPV for biopsy proven LSIL's from a smear with a cytological 
diagnosis of LSIL was 62.1 %. For women aged 20-49, the PPV for this category is 51-54%. 
For women in the 50-69 age group the PPV for this grade oflesion is 41-42%. For women 
70+ the PPV was 25.3%. 75% of smears with a diagnosis ofLSIL had to be excluded from 
PPV calculation because there was no histological diagnosis available. 
In the category of adenocarcinoma lesions the PPV for the cytological and histological 
correlation of this abnormality is 23-26% for women under 70; for women 70+ the PPV is 
56.6%. There is an absence of histological data in 25-50% of cases. 
PPV for LSIL 'sand HSIL 's - inconsistencies with the initial smear diagnosis: Age 
differences occur for the incidence of high grade lesions that are diagnosed from smears with 
cytological diagnosis of low grade lesions. There is a bimodal distribution in the incidence of 
biopsy proven HSIL's from smears with an initial cytological diagnosis ofLSIL's. In the 
<20 age group of26.3% of smears with the diagnosis ofLSIL's are in factHSIL's. For the 
following deciles these figures are 32.9% in 20-29 years, 25.8% in 30-39 years, 13.4% in 40-
49 years, 10.8% in 50-59 years, 13.3% in women 60-69 and 19.5% among women 70+. The 
more marked declines occur for women in the 40-70 age group who exhibit a halving in the 
incidence ofHSIL's appearing in smears with the initial diagnosis ofLSIL from, 19.5-32.9% 
in women <40 and >70 compared to 10.8-13.4% among women 40-69 years. 
The incidence ofLSIL's on smears carrying a cytological diagnosis of HSIL is also bimodal 
and is greatest for women under 20, PPV=32.6% declining for subsequent deciles - 18.9% in 
20-29 years, 15% in 30-39 years, then increasing to 16% in 40-49 years, 19.4% 50-59 years, 
14.6% 60-69 years and 16.7% for women 70+. 
The percentage of normal smears among low-grade lesions is 11-12% among women under 

































Among high-grade lesions the percentages of normal smears is smaller- 4-5.4% for women 
<40, 7.8-13.4 for women >40. 
Adenocarcinoma/AJS diagnosed from smears initially showing SIL: There is a trend showing 
an increasing incidence of biopsy proven adenocarcinomas from smears initially showing 
LSIL and HSIL's with age. The PPV for adenocarcinoma in smears with an initial diagnosis 
ofLSIL among women aged 20-29 is 0.06% increasing in subsequent deciles to 0.16% in 
women 30-39years, 0.4% in 40-49 years, 0.51 % for 50-59 years, 1.3% in 60-69 years and 
finally 8% among women aged 70 and upwards. In smears with an initial diagnosis ofHSIL, 
0.1 % of high grade smears contain adenocarcinomatous lesions among the 20-29 age group 
increasing to 0.34% in 30-39 years, 0.81 % in 40-49 years, 1.4% in 50-59 years, 1.8% in 60-69 
years and 7.6% for women aged 70+. For the expression of AIS there is a constant and small 
percentage <1 % of smears with an initial diagnosis of LSIL having AIS for women <70. 
Less than 1% ofHSIL smears conceal AIS in women under 30, 1-2% ofHISL smears 
contain AIS among women 30-69. 
6.1.1 Discussion of findings 
Large amounts of missing data make interpretation of PPV's difficult as PPV's can only be 
calculated for cytology where histology is present. Absent data may produce higher or lower 
values than those given depending on their degree of accuracy which is not known. Inter-
observer differences in the interpretation of cytology as discussed in chapter 2 may also give 
rise to discrepancies between cytology and histology. 
The findings for the PPV's for high grade lesions (correlation between HISL on cytology and 
histology) is similar to those contained in studies by Van der Graaf of 67-82%(Van der 
Graaf et al. 1987) and Soost - PPV 90% for severe dysplasia/CIS and 73 .4% for mild to 
moderate lesions. The lower PPV associating an LSIL smear diagnosis with histology may 
reflect the even greater quantities of the absence of histological data for verification as well as 
the use of the 1st abnormal smear in a series that led to further evaluation. The terminology 
for classification for the New Zealand register was different to those used by Soost and Van 
der Graaf. Van der Graaf (Van der Graaf et al. 1987) estimates of the PPV includes lesions 
in the following categories - those of severe dyplasia, carcinoma-in-situ and invasive cancer. 
Soost (Soost et al. 1991) does not state the upper and lower limits his category of mild-
moderate lesions and the lower limits for the category of severe dyplasia/CIS. The PPV's for 
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The latter study demonstrated differences in the PPV's according to the grade of the lesion. 
Higher PPV's were obtained for lesions of greater severity. PPV's calculated from the NCSP 
also display this differential. Studies by Van der Graaf and Soost (Van der Graaf et al. 1987, 
Soost et al. 1991) report a high specificity for cervical cytology. Since PPV's are a function 
of specificity it maybe that the predicted values would increase if histological verification 
could be obtained for all lesions. Predictive values calculated using NCSP data are based on 
an initial smear thus a portion of women showing abnormalities may have had a repeat smear 
yielding a more accurate diagnosis hence raising the value of the PPV's obtained particularly 
for the category of persisting LSIL's. It is not stated by Soost (Soost et al. 1991) whether the 
latter protocol of obtaining a repeat smear in the case of low-grade lesions was consistently 
applied in obtaining PPV's for their studies. 
The decrease in PPV's for HSIL's and LSIL's after the age of 50 is consistent with the 
decreasing prevalence of CIN with age. The latter concept also applies to the decreasing 
proportion ofLSIL's found on smears with an initial cytological diagnosis ofHSIL. 
Smears with an initial diagnosis of LSIL's concealing HSIL can be considered as false 
negatives. (10-33% ofLSIL smears turned out to be an HSIL) Such false negatives can reduce 
women's confidence in screening as the consequences of missing high grade lesions by smear 
diagnosis alone, would be serious. This is ameliorated by the screening process whereby a 
woman with a LSIL would have a repeat smear in 6 months and be investigated further only if 
the abnormality persisted. Thus in one sense the predictive value positive for an LSIL can be 
thought of as incorporating the findings of HSIL, AIS and adenocarcinoma. (being higher 
than the calculated value) Although there have been two recent major scandals involving 
erroneous reporting by pathologists involving hundreds of misread smears, false negatives of 
this type may also be attributed to the known possibility that LSIL's and HSIL's can coexist. 
(Crum 1997) Thus it is possible for the sample of cells obtained from the cervix to not be 
truly representative. The percentage values obtained for the LSIL smears yielding HSIL's 
should not be confused with the false negative percent of 11-20% quoted in chapter 4 across 
various studies which were derived by a more accurate method of assessing false negatives. 
A second peak among elderly women occurs for the incidence HSIL's occurring in smears 
diagnosed as being LSIL and may reflect the difficulty of obtaining a representative sample 
from the transformation zone which retracts with age or the tendency for transformation to 


























The consequence of false positive smears - smears initially diagnosed with HSIL but proving 
to be LSIL when biopsied is less serious but the impact is still significant. False positives 
create a lot of anxiety as women undergo unnecessary follow-up. Additionally health 
resources are wasted unnecessarily evaluating women that did not require follow-up. False 
positives may occur as a result of overdiagnosis due to conditions that mimic HSIL's, 
discussed in section 2.2 with pathologists erring on the side of caution in their assessment. 
Alternatively there may be some degree of spontaneous regression - 41-45% for CIN 2 across 
a range of studies quoted by Chanen (Chanen 1990) and 32% for CIN 3 quoted by Ostor 
(Ostor 1993) although this is very unlikely given the long time-spans of existence for SIL's 
described in chapter 2 and the protocol for management that mandates colposcopic 
examination within 1 month of diagnosis ofHSIL from a smear. 
The finding of an increasing incidence of adenocarcinoma with age, in smears with 
cytological diagnosis of SIL's may reflect the retraction of the transformation zone with 
menopause making it more difficult to adequately sample. Currently a range of sample 
instruments are available for use and the cytobrush is more superior to the cervibroom and 
spatula in sampling the endocervical canal. The current policy categorizes a smear without 
endocervical cells as being satisfactory but limited. Thus a women with a high endocervical 
lesion that is missed by a smear may be falsely reassured that her smear is normal or abnormal 
but not cancerous. However according to national guidelines any degree of abnormality 
within the spectrum of CIN automatically warrants further investigation. Thus the inability of 
the smear to make an exact diagnosis is ameliorated by protocols which provide guidelines for 




















7 DIRECT STANDARDIZATION OF MORTALITY RATES 
The main objective of the cervical screening program is to reduce the mortality from cervical 
cancer. In this chapter trends in mortality rates for cervical cancer will be examined 
beginning at the time deaths from cervical cancer were first accurately recorded. Since the 
age distribution varies with time, standardizing rates to a standard population in this case the 
1996 female population of New Zealand aged twenty and upwards, removes confounding due 
to age and enables comparisons to be made between different time periods. This is referred to 
as direct standardization which is different to indirect standardization where age-specific 
rates from some standard population are applied to the age distribution of the population at 
question to derive the total number of deaths that is expected among the population under 
study, which can be compared to the number of deaths observed in the study population. 
7.1 METHODOLOGY 
Age-specific rates (ASR) - deaths from cervical cancer per 100,000 using five year age 
intervals for women between 20-79 years old inclusive have been acquired from the New 
Zealand Health and Information Service. The period for which information on numerator 
data has been calculated is 1954-1996. The cancer registry was first established in 1948. 
Between 1948 and 1952 there have been a series of changes in the ICD classification of 
cervical cancer with some backdating of results. (personal communication with Stuart 
Sheppard NZHIS 1999) Population data for the age distribution of New Zealand women has 
been obtained from the New Zealand Health and Information Service based on census data. 
The average age-specific rate for five year periods has been calculated beginning at 1954. 
The use of averages may skew results towards extremes in rates. The alternative option - the 
use of a median value for 5 years, was similar to the values obtained for the calculated 
average, see appendix 2 for age-specific rates and medians for selected years. The cumulative 



































Information on mortality statistics terminates at 1996. For the last period a three year average 
has been calculated. These five year age-specific mortality rates have then been applied to a 
standard population - the 1996 female population from 20-80, to derive a figure for the 
expected number of deaths for the base year for which age-specific rates were used. The 
expected number of deaths for each five year period is converted to a mortality rate, using the 
standard population as the denominator. 
ASR for 20-24 x number of women in the age-group of the standard population = 
expected number of deaths 
25-29 x number of women in the age-group of the standard population= 
expected number of deaths 
75-79 
Sum of the expected number of deaths / total number in the standard population = 
age-standardized mortality rate 
(per 100,000 women) 
81 
7.2 RESULTS 
Table 7.1 mortality rates and expected number of deaths for cervical cancer in NZ women 1954-1958 
1954-58 5 year average ASR 1996 population Average number of expected 
per 100,000 women deaths 
20-24 0 136923 0 
25-29 0.55 140847 0.77 
30-34 1.6 151032 2.42 
35-39 8.24 145920 12.02 
40-44 9.69 129597 12.56 
45-49 12.39 120942 14.98 
50-54 19.02 93366 19.59 
55-59 20.98 79821 15.18 
60-64 19.02 67848 18.27 
65-69 23.42 67791 15.88 
70-74 35.5 61896 21.97 
75-79 32.16 48729 15.67 
Totals 1244712 149.31 
Age-standardized rate 149.31/1244712= 
12.0 per 100,000 women 
Table 7.2 mortality rates and expected number of deaths for cervical cancer in NZ women 1959-63 
1959-63 5 year average ASR 1996 population Average number of expected 
per 100,000 women deaths 
20-24 0.26 136923 0.36 
25-29 0.29 140847 0.39 
30-34 3.71 151032 5.6 
35-39 7.82 145920 11.41 
40-44 8.42 129597 10.91 
45-49 18.98 120942 22.98 
50-54 12.92 93366 12.06 
55-59 20.85 79821 16.64 
60-64 19.59 67848 13.29 
65-69 29.13 67791 19.75 
70-74 25.67 61896 15.89 
75-79 31.76 48729 15.48 
total 1244712 144.73 
Age-standardized rate 144.73/1244712= 
11.63 per 100,000 women 
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Table 7.3 mortality rates and expected number of deaths for cervical cancer in NZ women 1964-68 
1964-68 5 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
20-24 0.19 136923 0.26 
25-29 1.52 140847 2.14 
30-34 2.98 151032 4.5 
35-39 5.66 145920 8.22 
40-44 11.93 129597 15.46 
45-49 13.65 120942 16.5 
50-54 18.14 93366 16.93 
55-59 17.67 79821 14.1 
60-64 16.41 67848 1.13 
65-69 22.83 67791 15.48 
70-74 23.86 61896 14.77 
75-79 28.04 48729 13.77 
totals 1244712 133.15 
Age-standardized rate 133.15/1244712= 
10.7 per 100,000 women 
Table 7.4 mortality rates and expected number of deaths for cervical cancer in NZ women 1969-73 
1969-73 5 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
20-24 0.174 136923 0.23 
25-29 1.03 140847 1.45 
30-34 3.82 151032 5.46 
35-39 6.67 145920 9.74 
40-44 8.19 129597 10.62 
45-49 10.6 120942 12.82 
50-54 17.82 93366 16.64 
55-59 15.88 79821 12.68 
60-64 17.46 67848 11.84 
65-69 17.86 67791 12.11 
70-74 20.55 61896 12.72 
75-79 21.63 48729 10.54 
total 1244712 116.85 
Age-standardized rate 116.85/1244712= 
9.39 per 100,000 women 
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Table 7.5 mortality rates and expected number of deaths for cervical cancer in NZ women 1974-78 
1974-78 5 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
24-24 0.46 136923 0.63 
25-29 2.37 140847 3.34 
30-34 4.15 151032 6.27 
35-39 4.7 145920 7.05 
40-44 6.85 129597 8.88 
45-49 9.38 120942 11.34 
50-54 14.29 93366 13.34 
55-59 17.28 79821 13.79 
60-64 19.74 67848 13.39 
65-69 20.87 67791 14.15 
70-74 23.91 61896 14.80 
75-79 21.59 48729 10.52 
Total 1244712 117.5 
Age-standardized rate 117.5/1244712= 
9.44 per 100,000 women 
Table 7 .6 mortality rates and expected number of deaths from cervical cancer in NZ women 1979-83 
1979-83 5 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
20-24 0.14 136923 0.19 
25-29 2.63 140847 3.70 
30-34 4.53 151032 6.84 
35-39 7.18 145920 10.76 
40-44 5.13 129597 6.64 
45-49 10.45 120942 12.64 
50-54 13.1 93366 12.23 
55-59 14.26 79821 11.38 
60-64 15.67 67848 10.63 
65-69 18.74 67791 12.7 
70-74 15.89 61896 9.8 
75-79 21 48729 10.23 
Total 1244712 107.74 
Age-standardized rate 107.74/1244712= 










Table 7. 7 mortality rates and expected number of deaths from cervical cancer in NZ women in 1984-1988 
1984-1988 5 year average 1996 population Average expected number of 
ASR per 100,000 women deaths 
20-24 0 136923 0 
25-29 1.76 140847 2.48 
30-34 3.32 151032 5.01 
35-39 7.52 145920 10.97 
40-44 9.31 129597 12.07 
45-49 14.13 120942 17.09 
50-54 10.26 93366 9.60 
55-59 11.88 79821 9.48 
60-64 13.52 67848 9.17 
65-69 11.39 67791 7.72 
70-74 19.05 61896 11.79 
75-79 22.22 48729 10.83 
total 1244712 106.21 
Age standardized rate 106.21/1244712= 
8.53 per 100,000 women 
Table 7.8 mortality rates and expected number of deaths from cervical cancer in NZ women 1989-93 
1989-93 5 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
20-24 0.14 136923 0.19 
25-29 1.57 140847 2.21 
30-34 2.57 151032 3.88 
35-39 6.42 145920 9.37 
40-44 8.77 129597 11.37 
45-49 9.26 120942 11.2 
50-54 9.5 93366 8.87 
55-59 11.4 79821 9.1 
60-64 10.6 67848 7.19 
65-69 14.32 67791 9.71 
70-74 13.96 61896 8.64 
75-79 15.47 48729 7.54 
Total 1244712 89.27 
Age-standardized rate 89.27/1244712= 































Table 7 .9 mortality rates and expected number of deaths from cervical cancer in NZ women 1994-96 
1994-96 3 year average ASR 1996 population Average expected number of 
per 100,000 women deaths 
20-24 0.24 136923 0.32 
25-29 0.96 140847 1.35 
30-34 2.46 151032 3.72 
35-39 4.46 145920 6.51 
40-44 5.87 129597 7.6 
45-49 7.08 120942 8.5 
50-54 10.21 93366 9.5 
55-59 9.73 79821 7.77 
60-64 10.37 67848 7.04 
65-69 13.54 67791 9.18 
70-74 15.92 61896 9.85 
75-79 12.03 48729 5.86 
Total 1244712 77.2 
Age-standardized rate 77.2/1244712= 
6.2 per 100,000 women 
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7.2.1 Discussion of results 
Since 1954 there has been a gradual and consistent reduction in mortality rates, a decline that 
may have been part of a downward trend present prior to the period for which data has been 
analyzed. This is similar to the downward trend in age- standardized rates that has been 
demonstrated by Cox (Cox B. 1995, see appendix 3) Applying the age distribution of a 
standard population (1996) to mortality rates in 1954-1958, there is a reduction in mortality of 































the magnitude in reduction shown by Cox's data (Cox 1995) due to a difference in the 
standard populations that have been used to derive age-standardized rates. An age-
distribution that gave greater weight to women in the younger age groups than the older age 
groups where the majority of deaths occur, would yield lower values for age-standardized 
rates than those that have been displayed. Since an organized screening program was not 
effective until recently - 1990, its full impact will be seen in the years and decades to come. 
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The age-specific rates in 1989-1996 are similar to the projections made by Cox and Skegg 
(Cox and Skegg 1992) for the scenarios of improved screening and health education services. 
In many instances the age specific rates fall slightly under those predicted for the latter 
scenanos. 
Age-specific rates demonstrate consistent declines for most age groups in the last 40 years 
with young women under the age of 35 experiencing a slight increase in mortality between 
1974 and 1983 compared to earlier and subsequent periods. If there was a progressive 
increase in the numbers of women opting for screening in subsequent decades, then the 
reduction in age-specific rates reflects the efficacy of screening in improving survival for 
women by detecting disease at an earlier stage. If screening was not effective then the 
detection of disease at an earlier age and stage might lead to death at similar ages or death 
from cervical cancer occurring in the latter years of life (delayed death) in subsequent 
populations that had a greater uptake of screening therefore yielding no overall reduction in 
the age-adjusted mortality rate. 
Some age groups experience greater reductions in mortality than others after the onset of the 
organized screening program. For example women in the age brackets of 45-49 and 75-79 in 
1984-1988 compared to 1994-1996 express a halving of mortality rates which is greater than 
any other age group in that period. The age groups with the highest mortality rates up to 1979 
have been women 65+ exhibiting rates just above 20/100,000. After 1979 these rate decrease 
below 20/100,000 for women between 65-74 with further declines occurring in 1989-1996. 
Such reductions may be due to organized screening, alternatively they can be attributed to the 
latent effect of opportunistic screening activity prior to the onset of an organized program. 
The success of screening for cervical cancer is due to the ability of the pap smear to detect 
preclinical disease when removal of the lesion can effect a 100% cure. Detection of cancer 























with invasive disease detected by screening is difficult to quantify and inappropriate to 
discuss in the context of screening. Thus the reduction in mortality in subsequent years if 
there was an increased uptake in screening, will be due to the removal of lesions in their 
preclinical non-invasive and micro-invasive phase. Regardless of which ever phase of the 
disease screening has had the greatest impact, it has achieved marked reductions in mortality. 
The effect of confounding by fluctuations in the local population due to changing patterns of 
migration, hence the introductions or removal of risk factors associated with cervical cancer is 
controlled for by using a standard population. Age-specific rates may still fluctuate according 
to migratory patterns. The 1996 census reported an increase of 14.7% compared the 1991 
census, of people born overseas as opposed to an increase of 1.3% of those born in New 
Zealand. The fastest growing group was from Northeast Asia accounting for over half the 
increase in overseas born people living in New Zealand, followed by significant growth in 
Southeast Asians and Africans.(Statistics New Zealand 1998) These countries have higher 
rates of cervical cancer compared to New Zealand and may produce an increase in mortality 
rates in the future, an effect independent of screening particularly if these women were more 
averse to screening. People born overseas have been reported to have higher levels of 
education and lower levels of income and employment (Statistics New Zealand 1998) -
factors that contribute to the socioeconomic status which also influences screening uptake and 
mortality. 
From the available results it is impossible to discern any effect by other confounding factors 
hypothesized to contribute to the evolution of cervical cancer such as oral contraceptives and 
smoking which have become prevalent in later generations. The analysis of incidence data for 
emerging or changing patterns of carcinoma-in-situ or severely dysplastic lesions (pre-cursors 
of cervical cancer) may shed some light on the effect of theorized risk-factors and their 




















8.1 EFFECTIVENESS OF SCREENING 
Cervical screening may reduce the risk for women of developing invasive cervical cancer by 50-
80%. (La Vecchia et al.1984, Van der Graaf et al.1988) The implementation of an organized 
program in England and Scotland has resulted in approximately a 35% reduction in the incidence 
of cervical cancer. (Walker et al.1998, Quinn et al.1999) In Scandinavian countries where 
organized screening has been in operation since the decade of the 60's, the lowering in mortality 
from cervical cancer has been in the magnitude of 25-77%. (Laara et al. 1987) 
The 50% reduction in age-standardized mortality rates among New Zealand women that has 
occurred over a 40 year period supports the effectiveness of screening in New Zealand. The 
reductions achieved have occurred gradually for the period analyzed. Whilst an organized 
program did not come into effect until 1990, prevalence studies in the 1980's observing the 
distribution of precursor lesions describes an active screening service that has been operational in 
New Zealand for some time, reflected in the gradual decline in mortality that has been displayed. 
Use of the age-standardization for evaluation allows comparison of the rates of different periods 
and the effectiveness of screening on impacting cervical cancer mortality. The magnitude of the 
effect will vary according to the standard population to which rates have been applied. 
The effect on mortality is not homogenous with the age groups that experienced the greatest 
reduction in mortality in the period after an organized program came into being - 1994-1996, 
were women aged 45-49 and 70+. This may also be attributed to the latent effect of screening 
activity in the 70's and 80's. 
The effectiveness of overseas programs is based on coverage of the majority of the eligible 
population. The New Zealand register shows the percentage of women enrolled in 1997 to be 








of 55; for 20-24 year olds just over 70% o.f;women are emolled; for women aged 65-69 
approximately 60% of eligible women are emolled. 
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. The reduction in coverage that is displayed in figure 8.1 isn't as much of a concern for young 
women as for older women who experience the highest incidence and mortality rates from 
cervical cancer as described in chapter 7. Additional information that is necessary for evaluation 
and not presented here, would be whether or not women are obtaining smears at the appropriate 
interval. IARC research (WHO 1988) incorporating an analysis of several large screening 
programs show that an interval of 3-5 years has the greatest impact on reducing mortality. 
Computer modelling has demonstrated that more frequent screening - 2 yearly or yearly will 
















The question of how best to encourage women to participate in screening and to continue with 
screening is one that requires a detailed analysis of attitudes and health behaviors among New 
Zealand women and may not be necessary if current participation rates can be maintained due to 
the latent impact of treatment of preclinical disease in younger women. Continued targeted 
subsidies on health-care for lower income groups should be maintained alongside ongoing 
general information resources for primary-care providers. The needs of Maori women need to be 
considered carefully as research by Pomare (Pomare et al.1995) has shown higher incidence and 
mortality rates from cervical cancer compared to non-Maori. Rates of decline or increase relative 
to non-Maori need also to be studied in the light ofrecent screening initiatives that have been put 
in place to meet the needs of Maori. 
In the absence of a dollar-value estimate of the cost-effectiveness of screening in the current 
environment, the reduction in mortality justifies screening (program) for cancer of the cervix. 
For screening commencing at a young age the cost-effectiveness ratio is higher because of the 
lower prevalence of cancer in this age-group thus increasing the cost of screening per case of 
cancer detected. Exact estimates of the cost-effectiveness of cervical screening is difficult 
because of the higher rates of regression of low-grade lesions that have been crudely estimated 
from previous longitudinal studies thus an unknown percentage of women receive unnecessary 
treatment. A separation of the categories of CIN 2 and CIN 3 with more conservative treatment 
of CIN 2 lesions if diagnosis can be made with certainty, screening beginning at a later age or 
screening offered to young women having one of the established risk factors, may offer a more 
cost-effective solution. 
Current protocols and resources have been sufficient but the question of efficiency with regards 
to the commencement of screening and intervals for smear-taking is elusive in the absence of 
precise clinical trials with regards to the natural history of preclinical disease and randomized 
trials on the impact of screening. 
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8.2 EFFICACY OF THE SCREENING TEST 
Although overseas studies show that the false negative rate is 11-20% for diagnosing 
malignancies and may be more for dysplastic lesions, there is no published New Zealand data on 
the subject. Due to the internal variance across the country for quality-control measures, 
preferences for use of smear-taking instrumentation, inter-observer error ... false negatives may 
hugely vary to those demonstrated internationally. 
Work undertaken to evaluate the sensitivity of the screening test described in chapter 5 has shown 
the cervical smear to be a sensitive instrument in detecting preclincial disease and invasive 
lesions. Currently a range of options are available with regards to implements used to obtain a 
smear with the proviso for the use of a cytobrush for women with signs and symptoms of cancer 
or menopausal or post-menopausal women. This fits with the findings of studies in chapter 4 that 
describe the superior ability of the cytobrush to sample the endocervical canal as well as known 
anatomical changes that take place among women with ageing. 
Positive predictive values are similar to overseas studies with some variations occurring in 
specific categories of lesion and age groups. The higher predictive values obtained for cytology 
for high grade lesions - 61-78% shows that cervical cytology can accurately identify 
abnormalities. The lower predictive values obtained for the low grade lesions - 41-62%, as low 
as 25% among elderly women may be an underestimate as women having subsequent smears 
may have had results more closely corresponding to histology. However this result does reflect 
the wisdom of current thinking which has been to obtain a second specimen at a later date for this 
category of lesions because pathology changes. The variation in the predictive value with age 
corresponds to estimates of the prevalence of precursor lesions in the population: higher 
predictive values are obtained for age groups known to have a greater prevalence of dysplasia. 
The disparities between cytology and histology show an upward trend with age for high grade 
lesions occurring in smears with an initial diagnosis of LSIL and a slight increase in the small 
percentage of adenocarcinomas on smears with an initial diagnosis of LSIL or HSIL with age. 
This may reflect some difficulty in obtaining samples during the postmenopausal period when the 






















The predictive values justify a screening program despite the prevalence of preclinical disease not 
being high, as they show a reasonably high level of accuracy in being able to predict the lesion 
diagnosed by the smear. Even though the PPV's for low-grade lesion are low, if true positives 
were accounted for in numerator data as described in the methodology data in chapter 6, this 
would yield higher values. 
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8.3 UTILITY OF NEWER TECHNOLOGIES 
Slide preparation techniques such as Thin prep and Cytorich filter 'debris' such as blood and 
mucus that may obscure the ability to identify cervical cells on a slide. The increased yield in 
detectable abnormalities is probably due to the improvement in the adequacy of the slide. The 
increase in detection of 50% for high and low grade lesions (Bollick et al. 1998, Papillo et 
al.1998) needs to be considered in the context of the background figure for the prevalence of 
abnormalities - approximately 5%, and a lower value for the number of specimens that are 
inadequate. Additionally specificity values for studies shown in table 5.3 reveal a high 
specificity for conventional cytology - 94-99%. (The specificity values quoted in the latter 
studies are higher than those observed in studies shown in table 5 .9 on the validity of HPV 
screening and should not be used for comparison because of the variation in thresholds used in 
diagnosis) Therefore proportionately the number of false positives in a cervical smear program 
may be few. However as described in chapter 6, there are significant numbers of women who 
undergo unnecessary evaluation due to smears that are read as HSIL's or LSIL's but eventuating 
in a less serious diagnosis. There may be some reduction in such 'false positives' with the use of 
slide preparation technology particularly if such errors were due to over-diagnosis in the presence 
of inadequacies of the preparation slides. 
Whilst expenses are incurred in acquiring this type of technology, it may balance out the need for 
unnecessary investigations and create the possibility for a reduction in screening smears if the 
devices enable an increase in true positive specimens. For a health service that is unable to afford 
expensive technology, effort is better concentrated on obtaining a good sample and having 
quality assurance measures built into laboratory procedures with clear guidelines that make 
provision for smears that are difficult to interpret. 
The sensitivities for the initial trials for Autopap - an image analyzing device state values that are 
similar or lower than those obtained from conventional cytology. For example the sensitivity for 
detection ofLSIL was 60% (Patten et al.1998 CAS trial) compared to 78% for mild-moderate 
dysplasia (Soost et al. 1991); sensitivity for HSIL 80% (Patten et al. 1998 CAS trial) compared to 
81.4% (Soost et al.) and 87% (Hall et al. 1996). Higher sensitivity values were obtained using 


















obtained values close to 100%. (Jenny et al.1997) Despite classification differences for the pre-
Bethesda system era of studies, newer technology is not an imperative but will enhance any 
system by increasing the yield of true positives. Image analyzing devices confer the ability to 
reduce false negatives which overseas literature has indicated is a significant problem. Such error 
has been shown to be due to sampling inadequacies as well as the interpretational ability of the 
pathologist. The entry of new technologies also carries with it the burden of ensuring quality 
control methods that maintain the performance and operation of these systems. 
HPV screening is a separate issue. In the absence of a body ofliterature that is able to define the 
risks of developing SIL's in the presence of a positive HPV test, HPV screening confers the 
potential of an adjunct for conventional cytology. There is insufficient evidence to show 
substantial improvements in case-finding using HPV as a screening device. One of the major 
issues complicating HPV testing is the relative degree of uncertainty surrounding a positive test 
as many women with normal cytology have also tested positive in the studies described in table 
5.5. Although it is known that the high-risk HPV types are 16, 18, 31 and 45, many women with 
normal cytology have tested positive for these high-risk types (from studies contained in table 
5.9) The principles of screening should therefore remain unchanged, which are to treat the visible 





8.4 FUTURE DIRECTIONS 
More research is required into the biology and pathology of the human papillomavirus and its 
relationship to cervical cancer. This requires government policy that is committed to the 
development of an infrastructure that supports professionals and investment in technology. 
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Given that type specific viruses are associated with cervical cancer, surveillance data on 
serotyping could be used to alert and educate the public of risk. The value of such information is 
impaired by the long transit times associated with the development of a cancerous lesions but 
may be potentially useful with regards to the incidence of SIL' s. Once again as stated previously 
the utility of this knowledge is reduced in the absence of the unknown risk of developing cervical 
cancer associated with the presence ofHPV. Ultimately surveillance data and research into HPV 
should have the focus of developing a vaccine or cure for HPV. 
Standardization and agreement between professional bodies in this country is needed for the 
development of quality assurance measures applying to all laboratories. IANZ measures as 
described in chapter 5 are purposely broad to cover the huge range of services that laboratories 
deal with, pertaining to only the very basics of laboratory standards. A standard systems needs to 
be in place that is able to monitor without placing too many restrictions and is capable of 
backing-up ordinary human error. The use of image-analyzing devices may provide such an 
adjunct for the laboratory services. The cervical screening program has been operating 
successfully ( despite 2 recent inquiries) for nearly ten years and the time may be approaching to 
invest in technology which could be operated centrally thus reducing the costs to individual 
laboratories of purchasing these items. Additionally, indirect benefits are obtained by reducing 
the burden of diagnosis for pathologists. The benefits of such a move if it were considered as 
part of a centralized service need to be considered in the context of both a cost-benefit analysis 
where needs of other services outside the screening program and health service should be 
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Table 1 cytology and histology cervical smears 1993-1 996 Source:NCSP register 1999 
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APPENDIX2 
Table 2 Mortality rates for cervical cancer by 5 yr. age groups and year, selected means/medians 
Source:NZHIS 
20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- . 75-
1954 0.00 0.00 1.34 4.25 10.21 14.99 24.93 19.85 19.53 26.89 26.54 20.50 
1955 0.00 0.00 2.65 11.25 10.04 16.18 18.79 15.14 34.01 32.23 42.17 54.08 
1956 0.00 0.00 2.67 6.90 11.41 12.60 22.28 21.19 36.30 15.92 32.47 32.59 
1957 0.00 1.37 1.32 8.14 4.23 7.68 19.77 18.62 23.79 18.42 44.81 36.08 
1958 0.00 1.38 0.00 10.65 12.57 10.50 19.15 20.29 21.04 23.62 31.51 17.56 
mean 0.00 0.55 1.60 8.24 9.69 12.39 20.98 19.02 26.93 23.41 35.50 32.16 
median 0.00 0.00 1.34 8.14 10.21 12.60 19.77 19.85 23.79 23.62 32.47 32.59 
1959 0.00 1.39 1.32 10.52 11.09 29.43 20.22 13.94 34.46 39.26 34.08 51.59 
1960 1.33 0.00 2.65 11.77 8.28 15.93 14.77 25.37 13.55 26.10 18.31 33.86 
1961 0.00 0.00 6.64 6.51 9.57 22.89 9.59 26.68 17.68 23.39 21.14 25.07 
1962 0.00 0.00 3.96 6.45 4.01 15.44 10.91 16.75 17.41 29.84 39.66 24.45 
1963 0.00 0.00 3.98 3.86 9.14 11 .22 9.10 21.51 14.86 27.07 15.16 23.85 
mean 0.27 0.28 3.71 7.82 8.41 18.98 12.92 20.85 19.59 29.13 25.67 31.76 
median 0.00 0.00 3.96 6.51 9.14 15.93 10.91 21.51 17.41 27.07 21.14 25.07 
1964 0.00 2.64 2.67 6.42 15.33 15.45 16.25 27.75 12.38 19.55 17.86 19.67 
1965 0.00 3.79 4.04 8.97 18.95 15.34 21 .70 18.54 12.12 16.84 17.38 39.29 
1966 0.00 0.00 5.49 2.55 7.63 10.89 20.14 21.44 19.87 25.61 35.26 15.70 
1967 0.00 1.16 2.70 2.57 7.58 14.76 25.52 9.66 15.40 32.04 28.90 46.47 
1968 0.96 0.00 0.00 7.81 10.15 11.82 7.10 10.98 22.26 20.11 19.88 19.05 
mean 0.19 1.52 2.98 5.67 11.93 13.65 18.14 17.68 16.41 22.83 23.85 28.04 
median 0.00 1.16 2.70 6.42 10.15 14.76 20.14 18.54 15.40 20.11 19.88 19.67 
1969 0.00 1.12 5.21 6.62 11 .48 12.95 17.11 15.37 23.39 10.97 11.13 22.76 
1970 0.00 1.10 2.50 8.11 6.39 5.15 24.06 21 .08 15.75 21.67 16.24 22.62 
1971 0.87 0.00 4.77 5.42 11 .51 9.01 22.30 11.90 13.68 16.82 26.61 29.80 
1972 0.00 2.01 3.42 4.02 7.71 12.95 13.66 14.80 18.31 22.23 23.49 14.79 
1973 0.00 0.93 2.19 9.19 3.88 12.94 11 .99 16.26 16.19 17.60 25.28 18.17 
1974 0.82 4.36 2.10 7.59 2.59 10.33 15.58 23.72 6.31 22.84 24.49 24.93 
1975 0.79 0.83 3.07 4.80 3.94 6.44 15.48 16.08 27.74 18.36 24.07 24.20 
1976 0.78 0.00 8.03 4.56 9.35 9.03 16.90 9.99 21 .29 23.00 16.51 23.38 
1977 0.00 0.82 4.83 2.20 7.95 10.46 9.12 24.05 18.41 21.06 27.62 16.34 
1978 0.00 5.82 2.74 4.35 10.44 10.63 14.35 12.57 24.95 19.07 26.85 19.10 
1979 0.00 2.53 1.75 4.33 3.81 6.82 17.03 16.62 11.13 17.14 8.67 24.58 
1980 0.00 4.22 6.76 9.63 4.86 13.95 6.59 12.43 17.39 23.83 8.36 21.33 
1981 0.00 3.29 2.51 6.19 3.52 9.68 16.05 13.65 10.47 24.81 22.55 23.31 
1982 0.72 0.80 9.15 2.93 9.05 11 .00 14.93 16.30 22.09 16.38 28.12 22.34 
1983 0.00 2.33 2.46 12.81 4.40 10.78 10.91 12.30 17.29 11 .53 11.76 13.48 
1984 0.00 3.05 4.85 3.47 10.75 18.24 13.82 9.61 14.11 14.90 19.14 7.86 
1985 0.00 0.00 4.76 10.09 5.29 18.71 5.63 13.72 15.27 14.71 16.90 28.10 
1986 0.00 1.47 3.97 8.27 8.22 9.54 9.80 5.51 5.65 16.17 18.61 27.40 
1987 0.00 3.56 0.77 9.91 9.86 15.13 11.02 18.06 18.38 11.15 20.26 29.03 
1988 0.00 0.70 2.26 5.84 12.41 9.03 11 .03 12.52 14.20 18.73 20.35 18.73 
1989 0.74 1.40 2.19 9.12 9.08 8.84 9.43 11.17 12.84 9.42 5.59 11.54 
1990 0.00 2.78 2.86 5.71 11 .38 11.03 12.79 17.19 12.83 18.44 14.96 15.60 
1991 0.00 1.44 5.05 8.01 9.25 10.73 11 .27 5.83 9.97 19.56 21.51 15.55 
1992 0.00 0.00 1.40 6.23 8.34 10.03 4.74 8.67 7.20 18.12 19.19 13.00 
1993 0.00 1.51 1.37 3.04 5.78 5.65 9.25 14.20 10.18 6.05 8.53 21.66 
1994 0.00 0.00 2.71 3.68 10.55 3.57 10.18 9.64 7.39 16.66 13.37 8.67 
1995 0.73 0.75 2.03 2.85 5.53 10.24 15.44 14.55 8.99 13.64 19.84 15.03 









fig.1 Age-standardized mortality rate for cervical cancer for New Zealand women past and projected values 
Source: Cox B. Projections for cancer burden in New Zealand 1995 
Age-standardised rate (per 100,000) 
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Table 3. Summary of data of Thin-prep versus conventional smear Source Austin and Ramzy Increased etection 
of epithelial abnormalities 1998 
Reference Cases ThinPrep LSIL+ Conventional LSIL+ Increased% 
(ThinPrep Beta Model) 
Hutchinson et al, 1991 18 443 88 85 4 
Hutchinson et al, 199217 2,655 397 345 15 
Awen et al, 19932 1,000 18 13 38 
Wilbur et al, 199443 3,218 647 572 13 
Aponte-Capriani et al, 1995 1 665 25 23 9 
Bur et al, 19957 128 27 27 0 
Laverty et al, 199523 1,872 201 184 9 
McGoogan ef al 199628 1,493 68 83 (-18) 
Tezuka et al, 199640 215 117 122 (-4) 
Wilbur et al, 199644 259 40 43 (-7) 
1st PMA (site 1 )46 498 144 127 13 
1st PMA (site 2)46 775 309 279 11 
1st PMA (site 3)46 364 49 65 (-25) 
1st PMA (site 4)46 995 57 37 54 
1 st PMA (site 5)46 565 85 80 6 
ThinPrep Beta Model totals 15,145 2,272 2,085 9.0 
(not FDA approved) 
(ThinPrep 2000) 
Hutchinson et al, 199519 8,635 444 420 6 
Lee et al, 1997-2nd PMA26 6,747 637 538 18 
Laverty et al, 1997 22 51,437 1,885 1,583 19 
Corkill et al, 19988 1,583 88 42 105 
ThinPrep 2000 total 
(FDA approved) 68,402 3,054 2,583 18.2 
Overall ThinPrep totals 
(Thin Prep Beta+ Thin Prep 2000) 83,547 5,326 4,668 14.1 
Table 4. Summary of data Autocyte versus conventional smear Source Austin and Ramzy Increased detection of 














1 t: ':\, ,;., -.IJ 
Cases PREP LSIL+ Conventional LSIL+ Increased% 
CytoRich Beta Model ·.:"; 
Geyer et al, 199312 551 73 69 6 ~+ Scherr et al, 199433 350 63 58 9 McGoogan et al, 199628 1,598 55 61 ,:{ 
Sprenger et al, 199639 (-10) '\f 2,863 1,180 1,093 8 } CytoRich Beta Model totals 5,362 1,371 1,281 7.0 1J (AutoCyte PREP) 
Johnston et al, 199521 245 53 45 18 
. ~:i..' 
Learmonth et al, 199524 
{Y··1' 
422 43 40 7 j Bishop, 19974 468 75 45 67 Wilbur et al, 199745 286 26 12 117 Vassilakos et al, 199741 560 26 21 24 PMA (masked) totaJs11 8,983 509 467 9 
I 
AutoCyte PREP totals 
,· 
10,964 732 630 16.2 .· ~r·.f Overall AutoCyte PREP totals !<~t 
(CytoRich Beta + AutoCyte PREP) 
..... 






Table 5 summary of studies of Papnet testing Source Mango Neural Network Scanning 1998 
Definition 
of positive Metric 
HSIL+ No. of positives detected with device in primary 
mode vs. conventional 
ASCUS+ Sensitivity to positives 



















mode vs. conventional alone 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
No. of FNs detected by rescreening with device vs. 
with conventional rescreening 
Papnet sensitivity to FNs 
Conventional rescreening sensitivity to FNs 
Sensitivity to positives 
Sensitivity to positives 
Sensitivity to FNs 
No. of positives detected with device in rescreening 
mode vs. conventional mode 
Sensitivity to FNs 
No. of positives detected with device in rescreening 
mode vs. conventional mode 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to FNs 
Sensitivity to FNs 
Sensitivity to FNs 
Outcome measures 
RR= 1.39 
Sensitivity= 97% (58/60) 
RR= 1.29 
Sensitivity= 97% (31/32) 
RR= 1.10 
RR=0.74 
Detection of FNs = 67% 
Detection of FNs = 59% 
Sensitivity= 92% 
Sensitivity= 97% 
Sensitivity to FNs = 49% 
RR= 1.13 
Sensitivity to FNs = 60% (3/5) 
RR=l.18 
Sensitivity= 95% (153/161) 
RR= 1.55 
Sensitivity= 98% (124/127) 
RR= 1.09 
Detection of FNs = 95% (19/20) 
Detection of FNs = 50% (10/20) 
Detection of FNs = 100% 
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Citation 
Boon et al. Cell Vision 
1995;2:23-27 
Slagel et al. Diagn 
Cytopathol 
1995 ;13 :26-30 
Ashfaq et al. Diagn 
Cytopathol 
1995;13:31-36 
Boot et al. Mod Pa tho I 
1994;7:957-961 
Husain et al. Anal Cell 
Pathol 1994;6:157-163 
Koss et al. Am J Clin 
Pathol 
1994;101 :220-229 
Koss et al. Am J Clin 
Pathol 
1994;101 :220-229 
Ouwerkerk-Noordam et al. 
Cytopathol 
1994;5:211-218 
Sherman et al. Mod 
Pathol 1994;7:578-581 










































Sensitivity to positives 
Sensitivity to FNs 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to positives 
Sensitivity to FNs 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to FNs 
Sensitivity to positives 
No. of positives detected with device in primary 
mode vs. conventional 
No. of FNs detected by rescreening with device 
vs. with conventional rescreening 
No. of positives detected with device in primary 
mode vs. conventional 
No. of positives detected with device in 'primary 
mode vs. conventional 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to FNs 
Sensitivity to FNs 
No. of positives detected with device in 
rescreening mode vs. conventional mode 
No. of FNs detected by rescreen with device vs. with 
conventional rescreen 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to positives 
No. of positives detected with device in rescreening 
mode vs. conventional alone 
Sensitivity to positives (found by any method) 
No. of positives detected with device in primary 
mode vs. conventional 
Sensitivity to positives 
Sensitivity to FNs 
Sensitivity to positives 
Sensitivity to positives 
Sensitivity to FNs 
Outcome measures 
Sensitivity= 99% (719/725) 
Sensitivity= 98% (204/208) 
RR=l.46 
Sensitivity= 98% (311 /31 7) 
Sensitivity= 100% (56/56) 
RR= 1.23 
RR= 1.52 
20% Detection of FN 





Sensitivity= 89% (910/1,022) 
RR= 1.07 
Sensitivity= 90% (838/931) 
RR= 1.07 
Detection of FNs 58% of 19 
patients & 41 % in 29 smears 














Sensitivity= 56% (127/227) 
Tech code concordance= 95% 
Cytotechnologist concordance= 95% 
Positive predictive (HSI Ls)= 54% 
Positive predictive (LSI Ls)= 32% 
Cytopathologists agreed= 76% 
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Citation 
Data on file with NSI, 
August 1997 
Doornewaard et al. 
Acta Cytol 1997;41: 
74-78 
Killeen et al. Poster at 
American Society of 
Cytopathology, 
November 1997 
Kok et al. Cancer 
1996;78:112-117 
Farnsworth et al. Med J 
Aust 1996;165:429-431 
Rosenthal et al. Acta Cytol 
1996;40:120-126 
Koss et al. Hum Pathol 
1997;28:1196-1203 
Mango et al. Acta Cytol 
(1998;42:233-245) 
Ashfaq et al. Acta Cytol 
1997;4 l :1058-1064 
Michelow et al. Acta Cytol 
1997;41 :88-92 
Jenny et al. Acta Cytol 
1997;41 :82-87 
Halford et al. Acta Cytol 
1997;41:79-81. 





Table 6. Prevalence of HPV 16 and 18 in cervical adenocarcinomas, adenosquamous cell carcinoma and 
squamous cell carcinoma Source Kjaer and Brinto_n Adenocarcinomas of the uterine cervix 1993 
• I 
---· -- --··--, -··-· --,---
Adenocarcinoma Adenosquamous cell 
Squamous cell ;.~i 
Author and year Hybridization carcinoma carcinoma 
(reference) method No. of HPV HPV No. of HPV HPV No. of HPV HPV '1 
cases 16 (%} 18 (%) cases 16 (%) 18 (%) cases 16 (%} 18 (%) J: 
Tase et al., 1988 (50) In situ 40 3 40 44 19 19 24 54 0 '.i:: <?. 
King et al., 1989 (51) In situ 27 4 56 23 26 13 24 42 0 
Leminen et al., 1991 (52) In situ 206 2 14 .-/\~ 
Young et al., 1991 (53) In situ 21 0 0 
?-'.~ 
Walker et al., 1989 (54) Southern 
•,'~' 
25 20 32 11 8 27 62 63 6 .:I 
,_.-. 
blot ·;;~1; 
Riou et al., 1990 (55) Southern 17 24 59 74 61 8 
,.:.a 
::),}, 
blot+ PCR* ,;,~fA 
Bjersing et al., 1991 (56) PCR 26 15 27 
. .;;~ 
Griffin et al., 1991 (57) PCR 16 25 6 ::;~;; 
* HPV, human papillomavirus; PCR, polymerase chain reaction. ·gj 
,·,:.ll 
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